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Purpose: The purpose of this dissertation is to explore factors affecting accrual and 
completion of pediatric oncology clinical trials. This dissertation includes a scoping 
review of barriers and facilitators to enrollment in pediatric oncology clinical trials, a 
systematic review of trial-level factors affecting accrual and completion of oncology 
clinical trials, and an exploratory analysis of trial-level factors affecting accrual and 
completion of pediatric oncology clinical trials from ClinicalTrials.gov data. 
Problem/Aims: Cancer is the second leading cause of death in children. Clinical trials 
explore potential new therapies for children with cancer by determining safety and 
effectiveness of interventions. The literature demonstrates widespread inadequate accrual 
of trial participants and associated early termination of oncology clinical trials. This 
dissertation aimed to provide evidence of trial-level factors affecting accrual and 
completion of pediatric oncology clinical trials by reviewing the literature, identifying 
possible trial-level factors, and performing an exploratory analysis of the 
ClinicalTrials.gov dataset. 
Design including theoretical basis: A modified version of the Social Ecological Model 
and Arskey and O’Malley’s framework guided the scoping review. Bennette et al.’s 
framework, along with that of Knafl and Whittmore, directed the systematic review. 
Bennette et al.’s framework also guided the exploratory analysis using the 
ClinicalTrials.gov dataset. 
Findings: Barriers to enrollment in pediatric oncology clinical trials exist at the trial, 
individual, interpersonal and organizational levels. Several trial-level barriers to 
vii 
 
enrollment in adult oncology clinical trials previously were identified, such as 
enrollment, intervention type, phase, allocation, arm type, sponsor, number of 
participating facilities, and primary disease. The exploratory analysis indicated none of 
the aforementioned variables and others such as primary purpose, number of primary 
outcomes, interventional study model, and number of arms were predictive of early 
termination of pediatric oncology trials due to low accrual. However, odds for studies to 
terminate early were 4.7 times higher for those that used a data and safety monitoring 
committee compared to those that did not (p = 0.05). 
Conclusion: Findings from the scoping and systematic reviews suggest there are trial-
level factors that affect early termination of pediatric oncology trials due to low accrual. 
Findings from the exploratory study indicated that use of a data and safety monitoring 
committee plays an important role in early trial termination due to low accrual. The 
design of future pediatric oncology clinical trials should incorporate approaches to 
minimize trial-level factors that are associated with or predictive of early trial 
termination. Additional studies examining trial-level factors should utilize multiple trial 
databases and investigate pediatric oncology trials that have been conducted worldwide. 
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Cancer is the second leading cause of death in children, exceeded only by injuries. 
In 2020, 11,050 children ages 0-14 years are predicted to be newly diagnosed with 
cancer. Moreover, 1,190 children in this same age group years are predicted to die from 
cancer.[1] Cancer affects children of all ethnicities, socioeconomic backgrounds, and 
genders.[2] Available cancer therapies often result in toxicities, secondary cancers, and 
long-term financial challenges for affected children and their families.[3,4] Thus, new 
cancer therapies for children are urgently needed. 
Clinical trials explore potential new therapies for children with cancer by 
determining the safety and effectiveness of investigational drugs, devices, surgeries, and 
other interventions.[5] As a result of increased public pressure for more efficacious and 
less toxic cancer therapies, the number and costs of oncology clinical trials have 
increased. Thirty-two oncology clinical trials for children were opened in 2010, 
increasing to 137 in 2019.[6] Clinical trials for FDA-approved oncology drugs in 2015-
2017 had a median cost of $37.1 million per trial (interquartile range = $17.0 - $60.4 
million).[7] Consequently, the increase in number of oncology clinical trials and their 
associated high cost present challenges to their successful completion.  
The increase in number and high cost of oncology clinical trials present 
challenges to their successful completion due to required financial and human resources. 
Sponsors of clinical trials and cancer centers that participate in oncology clinical trials 
have limited resources to support the clinical and administrative operations necessary for 




conduct of clinical trials have decreased over time, while trial activation and maintenance 
are often complex and require many resources. For example, the activation of a phase III 
trial may consist of greater than 370 processes.[10]. 
The Institute of Medicine (IOM) cited inefficiencies in the development and 
conduct of clinical trials in the United States. One of these inefficiencies is the inability to 
prioritize trials likely to be most successful. The IOM’s report called for improvement in 
the speed and efficiency of the design and conduct of clinical trials, including the 
prioritization, selection, and completion of oncology clinical trials.[11] The lack of 
prioritization results in scarce resources being wasted or misappropriated to clinical trials 
that fail to successfully complete, thus impeding the availability of new, effective 
therapies for patients who desperately need them. 
The literature has demonstrated widespread inadequate accrual of trial 
participants and associated early termination of oncology clinical trials. One study 
revealed 40% of National Cancer Institute (NCI) Cancer Therapy Evaluation Program 
(CTEP) trials did not meet accrual goals.[12] In another study, more than 70% of phase 
III oncology trials reported inadequate accrual and only 37.9% of closed phase III trials 
reached their targeted accrual.[13] Moreover, one in five surgical randomized clinical 
trials is terminated prematurely because of inadequate accrual[14]. In addition, 
researchers have reported approximately one randomized clinical trial involving radiation 
failed to complete for every two of these types of trials that completed. Inadequate 




because an adequate sample size is required for valid trial results.[16] Consequently, 
accrual is an indicator of a clinical trial’s success. 
In addition to lack of validity of study outcomes due to small sample sizes, 
inadequate accrual can have several other negative effects on a clinical trial’s financial 
resources and participants. First, the enrollment period for a trial may need to be extended 
to obtain the targeted sample size, thus delaying results and increasing the trial’s 
costs.[17] Each additional month for the conduct of a phase 3 clinical trial regardless of 
therapeutic indication costs a median of $671,000.[18] Second, the early termination of a 
clinical trial due to inadequate accrual results in significant loss of financial and human 
resources that were utilized in the trials’ design, activation, recruitment, data collection 
and analysis, and management of the trial[19-21]. Consequently, those resources are not 
available to use for trials for the same target population that may have had a successful 
completion.[20] Third, the efforts of patients who participated in a clinical trial that 
terminates early due to low accrual have been in vain because the trial did not contribute 
knowledge in science.[17,19,20] Therefore, there are also ethical implications of 
inadequate accrual and early termination of clinical trials. 
Factors that affect the successful accrual and completion of oncology clinical 
trials operate at the trial, individual, interpersonal, organizational, community, and policy 
levels. Many researchers have investigated these factors for adult oncology clinical trials 
[22-36]; however, limited research exists about trial level factors that may affect 
successful accrual for pediatric oncology clinical trials. Trial level factors (e.g., eligibility 




and location) have been found to be associated with, or predictive of, completion of 
cardiovascular clinical trials, adult oncology clinical trials, and quality of pediatric 
clinical trials.[37-39] However, these trial level factors have not been investigated for 
pediatric oncology clinical trials, lest using a robust national dataset such as 
ClinicalTrials.gov. Precise estimates of which types of trials will be able to successfully 
meet their accrual targets based upon trial characteristics will support rapid translation of 
bench discoveries to therapies for children with cancer.[39] Identification of trial-level 
factors that affect the successful accrual and completion of oncology clinical trials is 
necessary for precise estimates. 
Over recent years, the government and public have insisted on transparency in 
clinical trials to facilitate drug development and safety. Subsequently, federal regulations 
were established to require sponsors of clinical trials to provide pre-defined data about 
their clinical trials in the ClinicalTrials.gov database.[6] Thus, ClinicalTrials.gov has 
become the largest and most inclusive database of clinical trials in the world due to it 
having the most predefined data[40] Changes in regulations instituted over the last two 
decades resulted in discrepancies in the type and amount of data that investigators 
submitted into the database during that timeframe.[6] As a result, the number of available 
variables differs among different time periods, study types (phase I, II, III, or IV), 
allocation (randomized or nonrandomized), and intervention model (parallel, crossover, 
factorial, or single-arm). Assessment of the completeness of variables in 
ClinicalTrials.gov may identify variables to be included in the design of future studies 




databases of clinical trials rather than data from a few clinical trials at a single or few 
institutions). 
Theoretical Models 
This dissertation includes a scoping review of barriers and facilitators to 
enrollment in pediatric oncology clinical trials, a systematic review of trial-level factors 
affecting accrual and completion of oncology clinical trials, and an exploratory analysis 
of trial-level factors affecting accrual and completion of pediatric oncology clinical trials 
from ClinicalTrial.gov data. Each of these investigations utilized a theoretical model to 
guide the data analysis and organization of the results. The scoping review of barriers and 
facilitators to enrollment in pediatric oncology clinical trials utilized a modified version 
of the Social Ecological Model (SEM) by McLeroy et al. [41] The SEM model was used 
because clinical trial enrollment is affected by a myriad of factors at multiple levels, 
including the trial, individual/intrapersonal, interpersonal, organizational, community, 
and policy levels. Trial-level factors affecting enrollment include the availability of a 
clinical trial, the status of the trial (e.g. open or closed), and eligibility criteria. Individual 
factors relate to study participants and include age, sex, race, ethnicity, insurance status, 
cancer characteristics, and motivation. Interpersonal factors include parents’ desire for 
continuity of care by healthcare providers, physicians’ discussions with parents and 
children about clinical trials, and physicians’ attitudes about clinical trials. Organizational 
factors include local availability of a clinical trial and continuity of care. Community 
factors include a culture of fear and distrust among minority groups because of 




includes laws that mandate insurance coverage for routine patient care costs associated 
with participation in clinical trials, hence lessening the financial burden of trial 
participation. 
Both the systematic review of trial-level factors affecting accrual and completion 
of oncology clinical trials and the exploratory analysis of trial-level factors affecting 
accrual and completion of pediatric oncology clinical trials utilized Bennette et al’s [42] 
conceptual model of trial-level factors associated with low trial accrual. The model offers 
four critical domains for assessing trial-level factors associated with low trial accrual: 
background, disease-related, treatment-related, and trial design. Background factors 
include greater competition from other trials and less state-level coverage of clinical trial 
costs. Disease-related factors include less advanced disease, solid tumor setting, less 
compelling scientific rationale, and lower annual incidence of the eligible population. 
Treatment-related factors include greater deviation from standard of care, research 
question not relevant to clinical practice, patient or provider preference for a particular 
treatment, radiotherapy or surgical treatment, not an investigational new agent, more 
expensive treatment, higher risk for toxicity, multimodality, and less compelling 
scientific rationale. Trial design factors include stricter or more eligibility criteria, 
randomized design, placebo-controlled arm, greater trial complexity, longer follow-up, 
and higher patient burden. 
Contributions of manuscripts 
Each manuscript in this dissertation compendium contributes to the identification 




clinical trials. The first manuscript, Barriers and Facilitators to Enrollment in Pediatric 
Oncology Clinical Trials, is a scoping review with the purpose of determining the state of 
knowledge of barriers and facilitators to enrollment in pediatric oncology clinical trials. 
Results and discussion were organized by trial, individual/intrapersonal, interpersonal, 
organizational, community, and policy levels. One finding of the review was the gap in 
knowledge about trial-level barriers and facilitators to enrollment in pediatric oncology 
clinical trials. Therefore, currently known trial-level barriers and facilitators to enrollment 
in adult oncology clinical trials were investigated in the second manuscript.  
The purpose of the second manuscript in this dissertation compendium, Trial-
level Factors Affecting Accrual and Completion of Oncology Clinical Trials: A 
Systematic Review, was to explore the literature to identify trial-level factors that affect 
accrual and/or completion of adult and pediatric oncology clinical trials, gaps in the 
literature, and prospective future research. A finding of this review was that none of the 
reviewed studies focused solely on pediatric oncology clinical trials and only three 
studies included a small number of pediatric trials. The identified trial-level factors 
identified in the first and second manuscripts, along with the available variables in the 
ClinicalTrials.gov dataset, informed the third manuscript. The identified trial-level factors 
and variables in the ClinicalTrials.gov dataset included enrollment, primary purpose, trial 
phase, interventional study model, number of arms, arm type, masking, allocation, 
intervention type, end points, number of primary outcomes, sponsors, number of 




The purpose of the third manuscript, Predictors of Early Termination of Pediatric 
Oncology Clinical Trials Due to Poor Accrual: An Exploratory Analysis, was to describe 
the presence of variables and completeness of data entry for variables in the 
ClinicalTrials.gov database over time. The frequency and proportion of pediatric 
oncology clinical trials with data for a given variable and data differed across four 
periods which were based on the effective dates of regulations affecting data 
requirements for ClinicalTrials.gov. The manuscript also reports on the investigation of 
trial-related factors that may predict early termination of pediatric oncology clinical trials 
due to low accrual. Results showed that use of a data and safety monitoring committee 
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Scoping Review: Barriers and Facilitators to Enrollment in Pediatric Oncology Clinical 
Trials (accepted for publication by Pediatric Nursing)  










Cancer is the second-leading cause of death among children in the United States. 
Oncology clinical trials are designed to investigate new potential therapies. 
Approximately 60% of children with cancer are treated on clinical trials. The purpose of 
this scoping review of the literature is to explore what is known about barriers and 
facilitators to enrollment in pediatric oncology clinical trials. Arskey and O’Malley’s 
methodological framework guided the scoping review. The electronic databases of 
PubMed and SCOPUS were searched for relevant publications. Thirty publications met 
eligibility criteria, which included empirical publications related to barriers and 
facilitators to enrollment in pediatric oncology clinical trials. The results and discussion 
of barriers and facilitators were organized by utilizing a modified version of the Social 
Ecological Model (SEM). Trial-level barriers included lack of an available trial, trials 
closed to accrual, and eligibility criteria. Individual factors included age, sex, 
race/ethnicity, insurance status, cancer characteristics, and motivation. Interpersonal 
factors included parents’ desire for continuity of care by healthcare providers, physicians’ 
discussions with parents and children about clinical trials, and physicians’ attitudes about 
clinical trials. Organizational factors that influenced enrollment included local 
availability of a clinical trial and continuity of care. No studies of community or policy-
level barriers and facilitators were found. Theoretically based studies need to be 
conducted to identify factors at SEM levels not previously studied and investigate 




interdisciplinary collaboration among nurses and other professionals working at each 
SEM level is vital to surmount enrollment obstacles.  





Scoping Review: Barriers and Facilitators to Enrollment in Pediatric Oncology 
Clinical Trials 
 
Surpassed only by injury, cancer is the second-leading cause of death among 
children in the United States (American Cancer Society [ACS], 2020). In 2020, 11,050 
children under 15 years old are predicted to be newly diagnosed with cancer, and of 
these, 1,190 are expected to die (ACS, 2020). As evidenced by these statistics, new 
effective oncological therapies are needed for children. Oncology clinical trials are 
designed to discover safe and efficacious means to prevent, diagnose, treat cancer and 
manage its symptoms (National Cancer Institute [NCI], 2020). Clinical trials are 
responsible for the childhood cancer cure rate increasing from less than 10% to over 80% 
during the past 40 years (Children’s Oncology Group [COG], n.d.). There are over 1,900 
active oncology clinical trials for 1 – 17-year-old patients in the ClinicalTrials.gov 
database (U.S. National Library of Medicine, 2020). 
Enrollment is significant because it is a key metric in determining the success of a 
clinical trial, as optimal sample size is required for valid results (Melnyk & Morrison-
Beedy, 2012). Also, if a clinical trial is extended due to poor enrollment, its costs 
continue to rise resulting in budget deficits and wasted resources (Steinman et al., 2017). 
However, enrollment of participants in oncology clinical trials is a challenge. 
Approximately 60% of children with cancer are treated on clinical trials (COG, n.d.). 
Existing literature about barriers and facilitators to enrollment in pediatric oncology 
clinical trials is limited. Identifying factors inhibiting enrollment is imperative so that 
interventions addressing enrollment challenges be developed, implemented, and 




purpose of this scoping review of the literature is to explore what is known about barriers 
and facilitators to enrollment in oncology clinical trials for children. The research 
question driving this review is “What are the barriers and facilitators to enrollment in 
oncology clinical trials for children?”  
Methods 
Arksey and O’Malley’s (2005) methodological framework guided the scoping 
review. The authors chose this framework because it facilitates rigor and transparency in 
each stage, thus increasing the reliability of findings. The five stages of the framework 
that were utilized were (1) identification of the research question, (2) search for 
applicable studies, (3) selection of the most appropriate studies utilizing inclusion and 
exclusion criteria, (4) collation, and (5) summary of results.  
The authors conferred with a reference librarian to determine the best approach to 
search the literature for relevant studies (most recent search on November 23, 2019). A 
PRISMA flow chart graphically detailed the identified records, included and excluded 
records, and reasons for excluded records (Moher et al., 2009) (Figure 1). The titles and 
abstracts of the publications were evaluated for relevance based on inclusion and 
exclusion criteria. Inclusion criteria were empirical publications related to barriers and 
facilitators to enrollment in pediatric oncology clinical trials. Exclusion criteria included 
the following: non-English speaking; children over 21 years old; diagnoses other than 
cancer; publications solely related to the prevention, screening, and survivorship of 
cancer; interventions; commentaries, statements, and recommendations. There were no 




facilitators to enrollment in oncology clinical trials for children and 2) this scoping 
review was intended to summarize and analyze all applicable study results to date.   
Adhering to stage 2 of Arskey and O’Malley’s (2005) framework, the electronic 
databases of PubMed and SCOPUS were searched for relevant publications. Due to 
variations in terms used to describe enrollment of oncology clinical trials, the following 
key words with appropriate Boolean operators were utilized: (pediatric[Title/Abstract] 
OR children[Title/Abstract] OR adolescents[Title/Abstract] OR 
teenagers[Title/Abstract]) AND (cancer[Title/Abstract] OR oncology[Title/Abstract]) 
AND ("clinical trials"[Title/Abstract] OR "clinical research trials"[Title/Abstract] OR 
"therapeutic trials"[Title/Abstract]) AND (enrollment[Title/Abstract] OR 
accrual[Title/Abstract] OR recruitment[Title/Abstract] OR participation[Title/Abstract] 
OR selection[Title/Abstract]). Publications were limited to English language and peer-
reviewed journal articles. The reference lists of retrieved publications were also hand 
searched for primary sources and additional applicable publications. 
To accomplish stage 3 of Arskey and O’Malley’s (2005) framework, a scoping 
review matrix was used to organize the selected publications. Publications were 
organized by the following: author/date, purpose, country, ages of children, cancer type, 
sample size and description, number and type of sites/number of clinical trials/phase of 
clinical trials, study design/data collection methods, barriers/facilitators, SEM levels, and 
results.   
The results and discussion of barriers and facilitators to enrollment in pediatric 




Ecological Model (SEM) by McLeroy et al. (1988). This model was selected because 
clinical trial enrollment is influenced by factors at multiple levels. The modified SEM 
addresses trial, individual/intrapersonal, interpersonal, organizational, community, and 
policy levels (see Table 1 for definitions).  
Results 
The initial search produced 2,335 citations. With 715 duplicates removed, 1,564 
citations were removed due to ineligibility based on the review of titles and abstracts. Of 
the 59 remaining full-text publications, 30 met inclusion criteria (Table 2). These studies 
represented diverse settings, designs, and implementation strategies. The studies about 
pediatric clinical trials were conducted in multiple countries, with only 13 conducted in 
the United States. The majority of studies (n=23) specified a facility setting specializing 
in pediatric cancer or a database containing data about pediatric patients and/or pediatric 
oncology clinical trials. Almost half (n=13) did not specify types of cancers. Of those that 
did specify cancer type, leukemia was most frequently studied (n=15). Phase of clinical 
trial was specified for 17 studies (phase I or I/II=9; phase III/late phase=8). Most studies 
about clinical trials (n=18) did not specify number of clinical trials examined. Four 
studies involved only one clinical trial, while the remaining 26 studies involved anywhere 
from 2-26 clinical trials. Eighteen studies used quantitative methods, and 12 used 
qualitative methods. None of the studies used mixed methods. For the quantitative 
studies, the most frequent source of data were electronic databases containing data about 
pediatric oncology clinical trials and/or their participants (n=10) whereas for qualitative 




Social Ecological Model (SEM) 
Only four studies were explicitly based on a theoretical framework, and none of 
the studies relied on the SEM for the design or analyses. Of the 30 studies included in the 
final analysis, 18 addressed one level of the SEM, and seven addressed two levels. Only 
five studies addressed three or four levels of the SEM, and none addressed five or six 
levels. Most of the studies (n=26) addressed the individual/intrapersonal level of the SEM 
(Table 3).  
SEM Levels 
Trial  
Five studies examined trial-level barriers and facilitators to enrollment in pediatric 
oncology clinical trials. Trial-level barriers included lack of an available trial, trials 
closed to accrual, and eligibility criteria that children did not meet (Dechartres et al., 
2011; Dodgshun et al., 2014; Pole et al., 2017; Surun et al., 2018). Type of dosing in 
clinical trials also influenced enrollment. Adolescents were more likely to decline dose 
intensification trials than dose reduction trials compared to younger children (Tulstrup et 
al., 2016). 
Individual/Intrapersonal 
Twenty-seven studies examined several types of individual/intrapersonal barriers 
and facilitators to enrollment in pediatric oncology clinical trials. Demographic factors 
such as age, sex, race/ethnicity, parental language, insurance status, distance from cancer 
center, geographical and urban/rural residence have been examined (Aristizabal et al., 




et al., 2014; Shochat et al., 2001; Thomas et al., 2018; Winestone et al., 2019). In general, 
adolescents compared to younger children and Hispanics compared to non-Hispanics are 
underrepresented in oncology clinical trials (Aristizabal et al., 2015; Lund et al., 2009; 
Nooka et al., 2016; Shochat et al., 2001). Being of Asian and Arab/west Asian ancestry 
and greater distance from cancer center were associated with non-enrollment (Pole et al., 
2017). Males were also less likely to participate in clinical trials than females (Donnelly 
et al., 2017). Children who lacked insurance had lower rates of clinical trial participation 
(Shochat et al., 2001). Individual factors such as cancer characteristics have also been 
investigated in relation to enrollment of children in clinical trials (Aristizabal et al., 2015; 
Dodgshun et al., 2014; Donnelly et al., 2017; Eiser et al., 2005). Children with 
hematological cancers have higher clinical trial participation rates than those with other 
types of cancers (Dodgshun et al., 2014; Donnelly et al., 2017; Thomas et al., 2018). 
Other individual factors such as understanding of clinical trials and motivation for 
enrollment into pediatric oncology clinical trials have been investigated (Eiser et al., 
2005; Ingersgaard et al., 2018; Miller et al., 2013; Robertson et al., 2019). In one study, 
most mothers described the aim of a clinical trial as comparing old and new therapies, but 
they lacked understanding of randomization (Eiser et al., 2005). Parents’ and children’s 
motivations for trial participation include the following: hope for a cure, desire to try 
anything, continuity of care, maintenance of quality of life, increased life expectancy, less 
toxicity, and altruism (Barrera et al., 2005; Crane et al., 2019; Hinds et al., 2005; 




2019; Simon et al., 2006; Unguru, et al., 2010; van der Geest et al., 2016; Woodgate & 
Yanofsky, 2010). 
Interpersonal 
Interpersonal factors have been explored in relation to enrollment of children in 
clinical trials. Parents’ desire for continuity of care by healthcare providers can influence 
the decision to participate in a clinical trial (Barrera et al., 2005). Also, the content and 
quality of physicians’ discussions about clinical trials can affect parents’ perceptions and 
understanding of clinical trials, thus affecting the decision about trial participation 
(Byrne-Davis et al., 2010; Deatrick et al., 2002; Miller et al., 2014; Robertson et al., 
2019; Simon et al., 2006). A physician’s attitude about clinical trials or belief about what 
is in a child’s best interest can affect enrollment (Dechartres et al., 2011; De Vries et al., 
2010; Dodgshun et al., 2014; Pole et al., 2017; Robertson et al., 2019). In addition, when 
there is a conflict between parents and an adolescent about enrollment, parents’ wishes 
usually take precedence (Ingersgaard et al., 2018). Finally, a trusting relationship 
between healthcare providers and children/parents can facilitate trial participation 
(Woodgate & Yanofsky, 2010). 
Organizational, Community and Policy  
Five studies examined organizational barriers and facilitators to enrollment in 
pediatric oncology clinical trials. Lack of a locally available clinical trial adversely 
affects enrollment (Dechartres et al., 2011; Dodgshun et al., 2014; Surun et al., 2018). In 
contrast, one of the main reasons for participation in phase I clinical trials is that the trials 




et al., 2005). No studies of community or policy-level barriers and facilitators to 
enrollment in pediatric oncology clinical trials were found.       
Discussion 
Social Ecological Model (SEM) 
A key finding of this scoping review is that barriers and facilitators at several 
SEM levels influence enrollment of children in oncology clinical trials. According to 
SEM, interventions at several, if not all, of these levels will be required to substantially 
increase enrollment of children in oncology clinical trials.   
Trial 
Surprisingly, few studies examined trial-level barriers and facilitators to 
enrollment in pediatric oncology clinical trials. The main trial-level barriers examined 
were related to the availability of a clinical trial open for enrollment for children with 
cancer. Trial availability was influenced by the type of cancer targeted by pediatric 
oncology clinical trials. Determining the most prevalent childhood cancers that do not 
have available clinical trials is of the utmost importance. Clinical trials for these cancers 
can then be developed and implemented to establish the safety and efficacy of new 
treatments to benefit pediatric cancer patients. Also important is the coordination of 
opening clinical trials. Often there are multiple open trials that are competing against 
each other for enrollment of the same population. At other times, there are no open trials 
for that same population. Coordination of the opening of trials may help prevent these 




The number and types of research studies about trial-level barriers and facilitators 
that influence enrollment in pediatric oncology clinical trials is lacking compared to those 
about adult oncology clinical trials. Few characteristics of pediatric oncology clinical 
trials were investigated in relation to enrollment except for eligibility criteria and dosing 
schema. Unlike with pediatric oncology trials, much research has been conducted about 
trial-level barriers and facilitators that influence enrollment in adult oncology clinical 
trials. These barriers and facilitators include, but are not limited to, eligibility criteria, 
disease type, treatment type, research question, design complexity, phase of trial, planned 
sample size, sponsor, number of sites, and location(s) of sites (Adams-Campbell et al., 
2004; Al-Refaie et al., 2011; Baum, 2002; Bennette et al., 2016; Benson et al., 1991; 
Cheng et al., 2010; Diehl et al., 2011; Freedman et al., 2018; Go et al., 2006; Khunger et 
al., 2018; Kim et al., 2015; Kornblith et al., 2002; Logan et al., 2017; Massett et al., 2016; 
McKane et al., 2013; Meric-Bernstam et al., 2015; Moore et al., 2004; Penberthy et al., 
2012; Schroen et al., 2010; Schroen et al., 2011; Simon et al., 2004; Spiegel et al., 2017; 
Statler et al., 2018; Stensland et al., 2014; Swain-Cabriales et al., 2013; Tang et al., 2017; 
Tibes et al., 2011). 
The trial-level barriers for pediatric oncology clinical trials may be different than 
those for adults. Children are often diagnosed with different types of cancers than adults, 
thus the clinical trials target these different cancer types and have different eligibility 
criteria and treatments. Also, since childhood cancer is less prevalent than adult cancer, 
there are fewer sites participating in clinical trials. In addition, pediatric oncology clinical 




Most pediatric oncology clinical trials are sponsored by COG, which is supported by the 
NCI. Over 90% of children with cancer in the United States are treated at COG member 
institutions, which consist mainly of children’s hospitals and academic cancer centers 
(COG, n.d). Unlike pediatric clinical trials, most adult oncology clinical trials are 
sponsored by pharmaceutical companies (Lechleiter, 2015). Also, adult cancer clinical 
trials are conducted at many facilities besides hospitals and academic cancer centers, such 
as community hospitals and private physician offices. Additional research is needed to 
determine if the differences in sites and sponsors between adult and pediatric oncology 
trials affect enrollment. For example, those trials sponsored by pharmaceutical companies 
may have better enrollment than those sponsored by COG since pharmaceutical 
companies tend to have larger financial resources for advertising and participant 
incentives such as travel vouchers. 
Researchers have also examined many barriers and facilitators to enrollment in 
adult oncology clinical trials in detail. For example, the following eligibility criteria 
pertaining to characteristics of potential participants were related to poor accrual: the 
presence of comorbidities, poor performance status, advanced age, histopathology, past 
history of cancer, a current second cancer, inadequate laboratory results, fewer prior 
systemic chemotherapy regimens, and disease-specific inclusion criteria such as 
testosterone levels, PSA results, Gleason scores, and number of positive lymph nodes 
(Adams-Campbell et al., 2004; Al-Refaie et al., 2011; Bennette et al., 2016; Diehl et al., 
2011; Freedman et al., 2018; Go et al., 2006; Kornblith et al., 2002; Massett et al., 2016; 




2012; Schroen et al., 2011; Simon et al., 2004; Statler et al., 2018). Even in studies where 
eligibility criteria were found to influence enrollment in pediatric oncology clinical trials, 
specific eligibility criteria were not investigated to determine which of the criteria served 
as barriers to enrollment. Restrictive eligibility criteria may be able to be amended to 
facilitate enrollment while still maintaining internal validity of pediatric oncology clinical 
trials.   
Individual/Intrapersonal 
Almost all the studies examined barriers and facilitators to enrollment in pediatric 
oncology clinical trials at the individual level. Overall, the studies demonstrated 
disparities with enrollment in pediatric oncology clinical trials in relation to age, sex, 
race/ethnicity, language, and insurance status, same as demonstrated in the previously 
discussed studies about influential factors of enrollment in adult oncology clinical trials. 
These disparities may indicate Healthy People 2020’s objectives is to reduce health care 
disparities for cancer has not been met (U.S. Office of Disease Prevention and Health 
Promotion, 2019). Pediatric oncology clinical trials need to be developed and 
implemented to facilitate enrollment as they are the key to discovering and testing new, 
effective treatments. 
Desperation for a cancer cure and/or extension of a child’s life was consistently 
demonstrated as a motivation for clinical trial enrollment. When children and their 
parents receive a cancer diagnosis and/or a poor prognosis, they are overwhelmed and 
may not be able to think rationally about potential treatments and possible associated 




may be unable to rationally consider the possible lack of efficacy and presence of 
toxicities associated with treatments on clinical trials. Healthcare providers must ensure 
true assent and informed consent have been given before children are enrolled on clinical 
trials. 
Interpersonal 
The most commonly examined interpersonal barriers and facilitators to 
enrollment in pediatric oncology clinical trials were those related to parental consent. The 
content of physicians’ discussions with parents about clinical trials affected the parents’ 
perceptions and understanding of clinical trials, possibly affecting the parents’ decisions 
about their children enrolling in the clinical trial (Byrne-Davis et al., 2010; Deatrick et 
al., 2002; Miller et al., 2014; Robertson et al., 2019; Simon et al., 2006). Therefore, 
healthcare providers need to provide clear and comprehensive clinical trial information to 
parents to facilitate enrollment. 
When there was a conflict between parents and an adolescent about trial 
participation, parents’ wishes usually took precedence (Ingersgaard et al., 2018). 
Therefore, healthcare providers need to provide a supportive environment that facilitates 
communication and understanding between parents and children to avoid continuing 
conflict. Healthcare providers also need to ensure proper assent and informed consent 
procedures are followed, especially when a child’s wishes conflict with his parent(s). 
Organizational 
Only five studies examined organizational barriers and facilitators to enrollment 




adversely affected enrollment. Besides being a trial-level barrier, lack of an available trial 
can also be considered an organizational barrier influencing enrollment in pediatric 
oncology clinical trials. Even though an appropriate oncology clinical trial may exist for a 
child, the trial may not be open at the institution where the child is receiving care. Also, 
the child’s family may not have the resources to travel long distances to receive care at an 
institution that is participating in the trial. Grant-funded agencies and pharmaceutical 
companies should be incentivized to open pediatric oncology clinical trials at institutions 
that are strategically located to meet the needs of the most children as possible. In 
addition, since clinical trials are costly to operate, organizations should be encouraged to 
manage their limited financial and human resources, so they are able to financially open 
additional much-needed pediatric oncology clinical trials. When its not possible open 
new trials, centers can educate parents/adolescents about important trials that may be 
available at other institutions. 
Community and Policy 
None of the studies examined barriers and facilitators to enrollment in pediatric 
oncology clinical trials at the community and policy levels. The conduct of research 
about barriers and facilitators that influence enrollment in pediatric oncology clinical 
trials at the community and policy levels may require more time and financial resources 
than the conduct of research at the individual and interpersonal levels. Hence, current 
limited and competitive research funding may contribute to the unequal proportion of 
research about barriers and facilitators at the community and policy SEM levels that 




Barriers and Facilitators in General 
A finding of this scoping review is the majority of studies were conducted in 
Europe addressing barriers and facilitators that influence enrollment of children in 
oncology clinical trials. Barriers and facilitators investigated in this scoping review may 
not have the same influence as they have in other countries due to different cultures, 
healthcare delivery systems, and regulations. Thus, researchers and health care providers 
need to be cautious in applying specific study findings from one community or country to 
others. 
Findings from some studies exploring differences in enrollment for cancer type 
and insurance status differed from those of others exploring the same factors. Aristizabal 
et al. (2015) found no significant differences in enrollment for cancer type and insurance 
status. However, Shochat et al. (2001) found children who lacked insurance had lower 
rates of clinical trial participation. These conflicting findings may be due to different 
types of insurance available in the different states in which the children lived. Findings 
from several, but not all, studies suggest hematological cancers are associated with higher 
clinical trial participation rates than other types of cancers (Dodgshun et al., 2014; 
Donnelly et al., 2017; Thomas et al., 2018). These conflicting findings could be due to 
different types of cancers that were examined in the studies. Hematological cancers have 
a higher frequency than other cancers in children. If there are more patients with a certain 
cancer, it may be easier to enroll a larger number of participants into a clinical trial, 
compared to patients with rare cancers. 




Barriers and facilitators to enrollment in pediatric oncology clinical trials have 
been described in the literature. However, very few, if any, were examined at the trial, 
organizational, community, and policy levels. In addition, the sample of studies in this 
scoping review did not specify which factors were most influential on enrollment. The 
studies did not specify if some factors such as trial phase, age, and race/ethnicity were 
more influential than others based on the type of cancer targeted in clinical trials, patient 
demographics, and settings. 
The sample of reviewed studies generally lacked a theoretical framework and 
large sample sizes of clinical trials. Only four of the reviewed studies were theoretically 
based. In future studies, the utilization of theory to explore factors at all SEM levels will 
strengthen internal validity and increase interpretability of results (Melnyk & Morrison-
Beedy, 2012). Many of the reviewed studies also lacked a large sample size of clinical 
trials. In addition, many of them did not use a comprehensive database of clinical trials 
that includes trials conducted throughout a country or the world. Small sample sizes of 
clinical trials conducted in a single or few locations limit the generalizability of study 
results. 
Limitations 
This scoping review framed by the SEM presented a general synopsis of the 
current literature related to factors associated with enrollment of children in oncology 
clinical trials and identified opportunities for future research on this topic. However, the 
literature search may not have included all available studies in the published literature 




Moreover, since only one reviewer was available, selected studies included in the final 
review could not be assessed for inter-rater reliability based on the inclusion and 
exclusion criteria. 
Implications for Future Research 
Future research on enrollment in pediatric oncology trials should consider 
investigating barriers and facilitators at the trial, organizational, community, and policy 
levels and developing novel interventions to address factors at all SEM levels. Also, 
future studies on enrollment of children in oncology clinical trials can include large 
samples of clinical trials and utilize large databases of clinical trials conducted in 
multiple countries. Finally, more research is needed to understand the reasons for the 
contradictory findings in the sampled studies. 
With an increased incidence of childhood cancers and low pediatric participation 
rates in oncology clinical trials that may hold promise for future treatments, it is 
imperative that factors addressing enrollment challenges be examined and addressed. 
Many factors at each SEM level affect enrollment. Following a theory-based evaluation 
and synthesis of research about factors that influence enrollment in pediatric oncology 
clinical trials, this scoping review demonstrated a lack of adequate research. To address 
this gap, theoretically based studies with rigorous designs and adequate sample sizes need 
to be conducted to address factors at SEM levels not previously studied. Finally, 
interventions should address factors that influence enrollment while using innovative 
approaches, such as trial designs that eliminate unnecessary eligibility criteria; electronic 




oncology clinical trials; and organizational, community, and federal policies incentivizing 
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Table 1. Social Ecological Model: Levels of influence 
Levels of Influence Definition 
Triala Characteristics of clinical trials that affect enrollment 
such as phase, disease indication, and eligibility criteria 
Individual/Intrapersonal Personal characteristics that affect behaviors such as age, 
sex, and race/ethnicity 
Interpersonal Relationships that provide social support and contribute 
to one’s identity  
Organizational Formal institutions and informal social groups, including 
their policies and processes that influence members’ 
behaviors 
Community Formal or informal networks with their own social norms 
among people, groups, and organizations 
Policy Local, state, and national laws and policies that promote 
or regulate behavior 
aNote: Trial level added to adapted Social Ecological Model: Levels of Influence 
(Mitchell, 2010; Robinson, 2008)    
Mitchell, J.A. (2010). Social ecological factors influencing cancer-related preventive  
health behaviors in African American men. Ohio State University. 
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Trial-level Factors Affecting Accrual and Completion of Oncology Clinical Trials: A 
Systematic Review  
Abstract 
Background: Cancer is the second-leading cause of death in the United States. Clinical 
trials translate basic science discoveries into treatments needed by cancer patients. 
Inadequate accrual of trial participants is one of the most significant barriers to the 
completion of oncology clinical trials. 
Objective: The purpose of this study was to investigate trial-level factors that affect 
accrual and/or completion of oncology clinical trials, identify gaps in the literature, and 
indicate opportunities for future research. 
Design: A systematic review of the literature on trial-level factors that affect accrual 
and/or completion of oncology clinical trials was performed. Searches in PubMed and 
Scopus identified 6,582 studies. Based on eligibility criteria, 16 studies were selected for 
the review. Results were analyzed according to the following:  a) background factors, b) 
disease-related, c) treatment-related, and d) trial design. 
Results: Background factors that were investigated in relation to oncology clinical trial 
accrual and/or completion included sponsor, number and location of participating 
institutions, competing trials, time of trial opening, and fast-track status. Disease-related 
factors included the annual incidence and type(s) of targeted cancer. Several types of 
treatment such as drugs, radiation and surgery were examined in the studies. Trial design 
factors included trial development time, eligibility criteria, randomization, sample size, 
trial phase, placebo use, and required protocol procedures and their timing. 
Conclusion: With low patient participation rates in oncology clinical trials that hold 
promise for future treatments, it is imperative that trial-level factors affecting accrual be 









Trial-level Factors Affecting Accrual and Completion of Oncology Clinical Trials: A 
Systematic Review 
1. Introduction 
Cancer is the second-leading cause of death in the United States with 
approximately 606,520 deaths expected in 2020 (American Cancer Society [ACS], 2020). 
As pressure has escalated to expeditiously translate basic science discoveries into 
treatments that are urgently needed by cancer patients, the increased number of oncology 
clinical trials and exorbitant costs of conducting these trials have resulted in challenges to 
their completion. According to ClinicalTrials.gov, approximately 2,800 oncology clinical 
trials opened in 2015. This number grew to over 4,600 in 2019 (National Library of 
Medicine [NLM], 2020). The median cost of clinical trials for oncology drugs approved 
by the Federal Drug Administration (FDA) in 2015-2017 was $37.1 million per trial 
(interquartile range = $17.0 - $60.4 million) (Hsiue et al., 2020).  
With growth in the number of oncology clinical trials and limited resources to 
support the conduct of these trials, inadequate accrual of trial participants has become one 
of the most significant barriers to the completion of clinical trials. Only 3-8% of 
oncology patients participate in clinical trials (ACS Cancer Action Network, 2018). In 
addition, approximately 20% of oncology clinical trials fail to complete because of 
inadequate accrual (ACS Cancer Action Network, 2018). Patient accrual is a significant 
metric in determining the success of a clinical trial, as achieving the targeted sample size 
is required for valid results (Melnyk & Morrison-Beedy, 2012). Clinical trials are too 
frequently terminated early or extended due to inadequate accrual. This adversely impacts 
the financial and other resources of cancer trial sponsors and participating sites (Steinman 
et al., 2017). Most importantly, trials that are delayed or terminated early impede the 




In 2010, the Institute of Medicine (IOM) called for a substantial improvement in 
the efficiency, completion, and prioritization of clinical trials (IOM, 2010). To 
accomplish these objectives, precise predictions about a trial’s accrual and completion are 
vital in this time of limited research funding for governmental, academic, and corporate 
entities (Schroen et al., 2010). These precise predictions to meet the IOM’s objectives are 
only possible through a comprehensive understanding of the factors that affect accrual 
and completion of oncology clinical trials. The literature demonstrates that factors 
impacting accrual and completion of oncology clinical trials operate at the individual, 
interpersonal, organizational, community, and policy levels. Although many researchers 
have investigated factors at these levels and developed interventions such as patient 
navigation and communication training to address barriers, accrual and completion of 
clinical trials remain inadequate (Ahaghotu et al., 2016; Fouad et al., 2016; Hurd et al., 
2017; Ling et al., 2000; National Conference of State Legislatures , 2017; Wuensch et al., 
2017; Yusuf, 2004). It is unclear whether studies have adequately explored factors at the 
trial level that may affect successful accrual and trial completion, e.g., eligibility criteria, 
planned sample size, phase of study, study design, and use of randomization.   
The purpose of this systematic review was to examine the empirical literature to 
investigate trial-level factors that affect accrual and/or completion of oncology clinical 
trials, identify gaps in the literature, and indicate potential opportunities for future 
research. The following research question guided the review: Among studies that 
analyzed large data sets of clinical trials, which trial-level factors influenced accrual 





The authors consulted with a medical reference librarian to determine the best 
approach to search the literature for applicable studies. The PRISMA statement guided 
the systematic selection of literature included in the sample, and a PRISMA flow chart 
detailing the process was created (see Figure 1) (Moher et al., 2009). PubMed and Scopus 
databases were searched on February 24, 2020 for relevant publications. There were no 
date delimiters. The following search terms with appropriate Boolean operators in titles 
and abstracts were applied: (cancer OR oncology) AND (“clinical trials” OR “clinical 
research trials” OR “therapeutic trials”) AND (enrollment OR accrual OR recruitment) 
AND (“eligibility criteria” OR inclusion OR exclusion OR methodology OR design OR 
“randomized controlled trials” OR “randomized control trials” OR RCTs OR barriers 
OR challenges OR facilitators OR “facilitating factors” OR factors OR correlates OR 
pragmatic OR feasibility). Publications were limited to the English language published in 
peer-reviewed journals. The reference lists of retrieved publications were also hand 






             Fig. 1. Flow diagram for literature selection and inclusion. 
 
The initial search produced 6,582 citations (PubMed = 1,109 and Scopus = 
5,473). Five additional citations for peer-reviewed articles were identified from hand 
searching. The titles and abstracts of the publications were evaluated for relevancy based 
on inclusion and exclusion criteria. Studies were included if they were: a) empirical 
studies that analyzed trial-level factors that influenced accrual and/or completion of 




international clinical trial databases. Excluded were studies that investigated both 
oncological and non-oncological clinical trials, utilized a clinical trials database specific 
to a single institution or network of local institutions, or only examined individuals’ 
perceptions of trial-level factors that influenced accrual and/or completion of oncology 
clinical trials. Also excluded were qualitative studies, literature reviews, meta-analyses, 
dissertations, narratives, commentaries, workshop proceedings, and expert 
recommendations addressing trial-level factors. Upon evaluation, 6,555 citations were 
removed due to ineligibility based on the review of titles and abstracts. Of the 32 
remaining full-text publications, 16 met criteria to be included in the study sample. Of 
note, Scopus did not contain any eligible publications that were not already found in 
PubMed. 
The results and discussion of this review were organized according to the themes 
of Bennette et al.’s (2016) conceptual model of trial-level factors associated with low trial 
accrual. The model’s main themes encompass the following:  a) background factors, b) 
disease-related, c) treatment-related, and d) trial design. Background includes factors 
such as competition from other clinical trials and insurance coverage of patient 
procedures associated with clinical trials. Disease-related include factors such as annual 
incidence of cancer and cancer stage. Treatment-related include factors such as type of 
treatment (e.g. chemotherapy or surgical) and use of a single modality (e.g. radiation) as 
opposed to multiple modalities (e.g. chemotherapy and radiation). Trial design includes 
factors such as eligibility criteria and use of randomization.  
3. Results 




Trial-related factors that impact a study’s accrual and/or completion were 
examined in several contexts such as study design, population, type of cancer, sample 
size, trial phase, and database (Appendix 1). Fifteen studies were quantitative, and one 
study had a mixed methods design. All studies (n = 16) were at level 4 (e.g. retrospective 
cohort study) according to Melnyk’s hierarchy of evidence (Melnyk & Morrison-Beedy, 
2012). Also, all studies examined oncology clinical trials for adults, with only three 
including trials for pediatrics. The majority of the studies (n = 10) did not limit inquiry to 
a specific type(s) of cancer. Three studies specified multiple types of cancer. The 
remaining studies (n = 3) specified one type of cancer, two of which were lung cancer. 
Sample size ranged from 16 to 12,875 clinical trials. Almost half of the studies (n=7) 
included a sample of phase I, II, and III trials. Most of the remaining studies had a sample 
of phase I and II trials (n = 2) or phase II and III trials (n = 3). Two studies had a sample 
of only phase III trials. All studies (n = 16) used a national database(s) as the source of 
clinical trial data. The most commonly used database (n = 8) was ClinicalTrials.gov. 
Only one study utilized a theoretical or conceptual framework, which was Bennette et 
al.’s (2016) conceptual model of trial-level factors associated with low trial accrual. 
3.2 Conceptual Model of Trial-Level Factors Associated with Low Trial Accrual 
To organize the results and discussion, the authors of this systematic review 
utilized Bennette et al.’s (2016) model that conceptualizes trial-level factors associated 
with low trial accrual according to themes. Of the 16 studies included in the final 
analysis, the following themes were addressed: background factors (n = 10), 8 disease-
related (n = 11), 5 treatment-related (n = 8), and trial design (n = 14).  




Background factors affecting oncology clinical trial accrual and/or completion 
were reported in the literature. Sponsor/funder was one of the examined background 
factors. Amongst published phase III oncology clinical trials, industry sponsored trials 
were among the fastest accruing (Ruther et al., 2015). Also, with poor accrual being the 
most common cause of early terminated clinical trials, industry sponsored immune 
checkpoint inhibitor trials were significantly less likely to terminate early compared with 
those that were sponsored by federal and academic institutions (Khunger et al., 2018). 
Worldwide, industry sponsored trials were also significantly more likely to attain accrual 
sufficiency than government funded trials (Paul et al., 2019). Consequently, government 
sponsorship was a predictor of study failure of randomized clinical trials in radiation 
oncology (Nguyen et al., 2018). 
Clinical trial development time was another examined background factor. Cheng 
et al. (2010) measured trial development time from initial submission of the trial to the 
NCI Cancer Therapy Evaluation Program (CTEP) to the opening of the trial. Oncology 
clinical trials developed in < 12 months were significantly more likely to meet accrual 
targets than those developed in 12-18 months. In contrast, oncology clinical trials 
developed in > 24 months were significantly less likely to meet accrual targets than those 
developed in < 12 months and 12-18 months. 
Other background factors affecting oncology clinical trial accrual and/or 
completion were the number and location of participating institutions. Clinical trials 
conducted at a single institution were more likely to fail to complete than those conducted 
at multiple institutions (Nguyen et al., 2018; Stensland et al., 2014). Regarding location 
of participating sites, data from one study suggested that trials performed outside of the 




complete than those conducted solely in the United States (Stensland et al., 2014). 
Findings from another study demonstrated that the continental location of the principal 
investigator and trials conducted internationally were not significantly associated with 
study failure (Nguyen et al., 2018). Multinational trials were among the fastest accruing. 
However, there were no significant differences in accrual time between trials conducted 
in the United States compared to Europe among phase III oncology clinical trials (Ruther 
et al., 2015). 
Competing trials, time of trial opening, and fast-track status were background 
factors that were investigated in relation to oncology clinical trial accrual and/or 
completion. Among adult National Clinical Trials Network (NCTN) (cooperative group) 
cancer clinical trials, the number of competing trials was a predictor of low accrual, with 
a higher number of competing trials associated with low accrual (Bennette et al., 2016). 
Nguyen et al. (2018) examined completed and incomplete randomized clinical trials in 
radiation oncology that opened in consecutive time periods. Significantly more trials 
failed during each consecutive time period (11.8% before 2007, 34% in 2007-2008, and 
39.5% in 2009-2012). Hernandez-Torres et al. (2019) found trial start date prior to 2003 
was associated with lower accrual of older adults. Fast track review status designated by 
the Food and Drug Administration (FDA) was not associated with low accrual (Bennette 
et al., 2016).  
3.2.2 Disease-related 
Lower annual incidence of the targeted type(s) of cancer and larger required 
enrollment fraction of the eligible patient population were predictors of low accrual 
(Bennette et al., 2016). Among NCI Cooperative Group phase III clinical trials, fewer 




et al. (2015) found the fastest accruing trials among phase III oncology clinical trials 
were those for breast cancer. However, Hernandez-Torres et al. (2020) demonstrated 
breast cancer clinical trials were associated with lower accrual of older adults. Among the 
older population, clinical trials for central nervous system cancers were associated with 
higher accrual (Hernandez-Torres et al., 2020). There was no significant difference in 
adequate accrual between urological and nonurological trials. However, kidney cancer 
trials accrued the best, whereas bladder cancer trials accrued the worst among urological 
trials (Paul et al., 2019). Predictors of low accrual were trials for common solid cancers 
as opposed to rare solid or liquid tumors and those with inclusion criteria that targeted 
multiple types of cancer (Bennette et al., 2016).  
There were mixed results for the association between accrual and metastatic 
disease. In two studies, metastatic disease, compared to nonmetastatic disease, was a 
predictor of low accrual (Bennette et al., 2016; Lemieux et al., 2008). Also, early stage 
cancer was significantly associated with enrollment of older persons (Gross et al., 2005). 
However, in another study accrual was better for trials that involved advanced disease 
(Lyss & Lilenbaum., 2009).  
3.2.3 Treatment-related 
Treatment-related factors were investigated in the literature. Clinical trials that 
investigated immune checkpoint inhibitors were less likely to terminate early compared 
to those that investigated other types of oncology drugs, but the results were not 
statistically significant (Khunger et al., 2018). Predictors of low accrual included non-
targeted therapy and radiation therapy (Bennette et al., 2016). Accrual was poorer for 
Radiation Therapy Oncology Group trials than other cooperative groups and for 




2009). Whereas Bennette et al. (2016) found the use of an investigational new drug to be 
a predictor of low accrual, other researchers (Korn et al. 2010; Lyss & Lilenbaum, 2009) 
found no significant difference in inadequate accrual between clinical trials that involved 
a new investigational therapy and those that did not. Clinical trials involving standard 
therapy, with or without a new therapy, had better accrual than those that did not 
incorporate standard therapy (Lyss & Lilenbaum, 2009). Trials that compared surgery to 
other types of therapies such as drugs were associated with low accrual and/or trial 
failure, and multimodality clinical trials were associated with low accrual (Bennette et al., 
2016; Nguyen et al., 2018). 
3.2.4 Trial Design  
Our findings suggest eligibility criteria, randomization, sample size, trial phase, 
placebo use, and required protocol procedures and their timing affect accrual and/or 
completion of oncology clinical trials. The main reported reasons for slow accrual for 
phase I oncology clinical trials were safety/toxicity (48%), design/protocol issues (42%) 
and eligibility criteria (41%). In addition, the main reasons for slow accrual for phase II 
oncology clinical trials were eligibility criteria (35%) and design/protocol issues such as 
required procedures, treatment schedule, and overall complexity of the trial (33%) 
(Massett et al., 2016). Increased trial complexity defined by a higher number of targeted 
diseases in inclusion criteria, interventions and study locations was associated with low 
accrual (Bennette et al., 2016). 
 Sample size and phase of the clinical trial were two trial design factors that 
affected accrual and/or completion of oncology clinical trials, although with mixed 
results in studies. Bennette et al. (2016) found larger sample size was a predictor of low 




was higher for completed trials with a median sample goal of 47 compared with that of 
terminated trials with a median of 9. They also found phase II and phase III trials were 
significantly less likely to terminate early compared with phase I trials, with low accrual 
being the most common reason for early termination for all trials. However, Bennette et 
al. (2016) demonstrated phase III was a predictor of low accrual. Other studies did not 
show accrual varied by trial phase (Paul et al., 2019). 
 Eligibility is another trial design factor that affects oncology clinical trial accrual. 
Overall, eligibility criteria that place burdens on patients, such as those that require the 
collection of tissues that are not involved with standard of care, were associated with low 
accrual (Bennette et al., 2016). In a study of phase I to III molecular trials, the total 
number of eligibility criteria was significantly associated with the enrollment period’s 
duration in trials that had at least 35 enrolled patients (Kim et al., 2015). 
Specific types of eligibility criteria, which have the potential to considerably limit 
accrual, were examined in the literature. In a study utilizing ClinicalTrials.gov, the 
following exclusion criteria were in early phase clinical trials for breast, colorectal, or 
lung cancers: age > 75 years (6%), history of prior malignancies (86%), autoimmune 
disease with exceptions of vitiligo and alopecia (48%), any central nervous system (CNS) 
metastasis (38%), symptomatic CNS metastasis (34%), human immunodeficiency virus 
(31%), hepatitis B or C (21%), and atrial fibrillation (20%). Renal and hepatic eligibility 
criteria were prevalent, such as creatinine <1.5 of the upper limit of normal (ULN) 
(35%). Compared to targeted therapy clinical trials, chemotherapy clinical trials were 
more likely to have exclusion criteria pertaining to CNS metastasis and history of other 




criteria than those with other types of sponsors such as the NCI or universities (Duma et 
al., 2019).  
Other specific types of eligibility criteria were examined in the literature. In a 
study of Eastern Cooperative Oncology Group (ECOG) -affiliated lung cancer clinical 
trials, 80% excluded prior cancer diagnosis: active cancer (16%), any prior cancer (14%), 
within 5 years (43%), and within 2-3 years (7%). These exclusions were more common 
for phase II and III clinical trials (85%) compared to pilot/phase I clinical trials (25%). 
Estimated proportion of excluded prior lung cancer patients was up to 18% (>5% for 2/3 
of clinical trials and >10% for approximately 1/3 of clinical trials). Exclusion criteria 
related to prior cancer treatment were present in 39% (20) of clinical trials, with 29% (15) 
excluding chemotherapy or other therapy and 10% (5) excluding both that and 
radiotherapy (Gerber et al., 2014). Although in one study (Bennette et al., 2016) 
performance status (function, symptom burden, need for care) in exclusion criteria was 
not found to be associated with poor accrual in adult oncology clinical trials, performance 
status in exclusion criteria was significantly associated with enrollment of older persons 
in another study (Gross et al., 2005). However, exclusion criteria related to renal 
dysfunction were associated with lower accrual of older adults (Hernandez-Torres et al., 
2020). 
 Randomization and use of placebo were other trial factors studied regarding 
accrual and/or trial completion. Bennette et al. (2016) found the use of randomization to 
be associated with low accrual. This was further supported by pediatric nonrandomized 
clinical trials having adequate accrual (Korn et al., 2010). However, in another study, 
randomization was not found to affect accrual or the early termination of studies (Paul et 




trials by Lemieux et al. (2008), trials with no placebo were associated with better 
recruitment than those with a placebo. However, Bennette et al. (2016) found no 
associations between low accrual and placebo use. Also, Ruther et al. (2015) reported 
there were no significant differences in accrual time between placebo and non-placebo 
use in published phase III oncology clinical trials. 
 Required protocol procedures and their timing affected accrual in oncology 
clinical trials.  The requirement of obtaining a tissue sample to assess eligibility was a 
predictor of low accrual (Bennette et al., 2016). Better recruitment was associated with an 
allowed 12 week or more interval vs. less time from diagnosis, surgery, or end of 
previous therapy for nonmetastatic clinical trials (Lemieux et al., 2008). There was no 
association between blinding and length of follow-up and poor accrual (Bennette et al., 
2016). 
Other trial design factors were investigated in the literature. There were no 
associations for accrual related to age group, sex, intervention model, therapeutic 
compared with nontherapeutic treatment, masking compared with open label, primary 
purpose, and specialty (Paul et al., 2019). Among randomized clinical trials in radiation 
oncology, lack of accrual was the main reason for trial failure, and a safety endpoint as an 
outcome was associated with trial failure (Nguyen et al., 2018).  
4. Discussion 
In this systematic review, we examined the empirical literature to investigate trial-
level factors that affect accrual and/or completion of oncology clinical trials, identified 
gaps in the literature, and suggest potential opportunities for future research. One of the 
most striking findings was the limited number of studies that utilized large databases, lest 




oncology clinical trials. Researchers are no longer limited to studying clinical trials 
merely as a single trial or trials which involved a single or few institutions. 
ClinicalTrials.gov allows researchers to investigate clinical trials as an enterprise since it 
is the largest and most comprehensive clinical trial database in the world (Fain, 2018). 
There was the lack of a standard definition of adequate or inadequate accrual. For 
example, Paul et al. (2019) appeared to define insufficient accrual as anything less than 
100% of the trial’s minimum projected sample size whereas Bennette et al. (2016) 
defined low accrual as less than 50% of the target sample size. Different definitions for 
the outcome variable of adequate or inadequate accrual may partially explain discrepant 
results in the examined studies’ results.  
Background factors that were investigated in relation to oncology clinical trial 
accrual and/or completion included sponsor, number of participating institutions, location 
of the institutions, competing trials, time of trial opening, and fast-track status. The 
literature consistently demonstrated that industry-sponsored trials outperformed trials 
sponsored by other entities in accrual and completion. The pharmaceutical industry may 
have more financial resources to manage clinical trials at multiple worldwide institutions 
and invest in accrual strategies such as advertising and participant incentives such as 
travel reimbursements. Unsurprisingly, a higher number of NCTN-sponsored competing 
trials was associated with low accrual. Fast track review status designated by the FDA 
was not associated with low accrual which would be expected, given that fast tracking 
involves having study sponsors and the FDA working closely together to prioritize and 
expedite the conduct of clinical trials to get the investigational therapy approved and 




 The type of cancer and its annual incidence were disease-related factors that were 
investigated. Except among the older population, clinical trials for breast cancer trials 
consistently outperformed those for other types of cancers in accrual, possibly resulting 
from the high incidence of breast cancer and public awareness campaigns for these 
clinical trials. Predictors of low accrual were common solid cancers as opposed to rare 
solid or liquid tumors. Overall, there are more standard therapies available for common 
solid cancers than liquid and rare solid tumors. Therefore, patients with common solid 
cancers have more standard therapy options and do not have to rely on an investigational 
therapy, resulting in lower accrual in clinical trials.  
Several types of treatment were examined in the studies. Clinical trials involving 
radiation and surgery face challenges with accrual and/or completion. Patients may 
choose drug regimens, whether as standard therapy or in trials involving only drugs, to 
avoid the invasiveness and potential complications of a surgical procedure. Also, the 
proposed surgical procedure in a clinical trial may not have established efficacy in itself 
or compared to marketed drugs. In addition, patients may prefer drug regimens over 
radiation clinical trials because they do not want to complete frequent visits to a radiation 
facility as radiation therapy often entails daily administrations for many weeks. There 
were mixed results about accrual between clinical trials that involved a new 
investigational therapy and those that did not, likely due to the difference in toxicity 
profiles of the investigational agents. 
The following trial design factors were investigated: trial development time, 
eligibility criteria, randomization, sample size, trial phase, placebo use, and required 
protocol procedures and their timing. Eligibility criteria was the most frequently 




prognostic factors and a high risk of adverse events, eligibility criteria can adversely 
impact accrual and/or trial completion. Each eligibility criterion needs to be evaluated to 
ensure it is supported by the scientific literature and not included just because it was 
contained in previous protocols (Malik & Lu, 2019). Duma et al. (2019) also 
recommends eligibility criteria to be relaxed once a drug’s toxicity profile is better 
understood. 
Although trial-level factors that affect accrual and completion of oncology clinical 
trials have been discussed in publications, there remain gaps in the literature. Several 
trial-level factors have not yet been investigated utilizing ClinicalTrials.gov outside of 
studies that are sponsored by NCTN, focus on urological and non-urological solid 
cancers, and investigate radiation. These trial-level factors include primary purpose, 
randomization, blinding, and placebo use. In addition, there is a need for studies that 
characterize the relative importance of various trial-level factors driving clinical trial 
accrual and/or trial completion and to test the impact of including and excluding these 
driving trial-level factors on accrual. Research is needed to determine if trial protocols 
developed to minimize the inclusion of trial-related factors known to be significant 
barriers result in successful accrual. The reviewed studies did not indicate if some trial-
related factors were more influential than others based on the type of cancer targeted in 
clinical trials. In addition, although this systematic review examined diverse trial-related 
factors, the review did not address influential trial-related factors specific to patient 
demographics, except for older adults. Trial-related factors may differ in the way they 
affect accrual in clinical trials focused on different types of cancers or populations, such 
as pediatrics. Interventions to improve accrual may need to be tailored to clinical trials 




Studies utilizing a mixed methods design may increase knowledge about trial-
level factors that affect accrual and/or study completion. Mixed methods studies could 
explore participants’ views of, and experiences with, trial-related factors to improve 
accrual and/or trial completion.  This knowledge could assist researchers in developing 
and implementing efficient trial designs and effective interventions to increase accrual 
and completion of oncology clinical trials. These data would be helpful in determining 
which trial-related factors are modifiable. 
We found that several of the examined studies had conflicting results about the 
association between trial-level factors and accrual and/or completion of oncology clinical 
trials. Therefore, more research is required to further elucidate these associations. Only 
eight of the sample articles utilized ClinicalTrials.gov, thus future researchers should 
consider use of this database when studying trial-level factors that affect accrual as 
having a larger sample sizes of clinical trials would increase generalizability of results. 
Furthermore, clinical trials for different types of cancer encounter distinct challenges to 
successful accrual. The majority of studies included in this systematic review did not 
specify a specific cancer, so future research is vital to address trial-level barriers to 
accrual associated with individual types of cancer. Also, since most of the studies in this 
review focused on adult oncology clinical trials, similar research is needed for clinical 
trials for other populations such as pediatrics. Finally, focused efforts on the development 
and implementation of interventions to address the trial-level factors that adversely 
impact accrual are needed. This research will need to involve careful reflection about the 
modifiability of trial-level factors. Improved accrual may contribute to successful 
completion of oncology clinical trials in a timely manner, reducing the waste of financial 




 This systematic review has limitations. The literature search may not have 
included all available studies in the published literature because additional terms 
describing trial-level factors may have been omitted inadvertently. Moreover, since one 
investigator conducted the review, selected studies included in the final review could not 
be assessed for inter-rater reliability based on the inclusion and exclusion criteria. 
5. Conclusion 
With low patient participation rates in the increasing number of oncology clinical 
trials, it is imperative that trial-level factors affecting accrual be identified and 
interventions addressing these challenges be developed to facilitate the completion of 
trials. Following a theory-based evaluation and synthesis of research on trial-related 
factors that influence accrual in oncology clinical trials, this systematic review identified 
gaps in research in this area. To address the gaps in the literature, theoretically-based 
studies evaluating the association between trial-level factors and accrual/trial completion 
should be conducted. The use of theory guides the evaluation, analysis, and organization 
of data. In addition, researchers should simultaneously address background, disease-
related, treatment-related, and trial design factors that influence accrual using innovative 
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Results Specific to Trial Factors 
Bennette et al., 
2016 
Evaluate associations and 
predictors between trial-
level factors and low 
accrual in adult 
cooperative group cancer 
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-Predictors of low accrual included the following: higher 
number of competing trials, phase III, higher enrollment 
percentage of eligible population, non-targeted therapy, 
radiation therapy, lower annual incidence of clinical 
condition, tissue sample required to assess eligibility, 
non-new investigational drug, metastatic setting, sample 
size, more than one condition, and common solid cancer. 
-Other factors associated with low accrual were 
multimodality, surgery, arduous eligibility criteria, 
randomization, and trial complexity including number of 
interventions, number of study locations, and more than 
one disease.   
-There were no associations between low accrual and 
placebo use, length of follow-up, fast track review, 
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-CTs developed in < 12 months were significantly more 
likely to meet accrual targets than those developed in 12-
18 months.  
-CTs developed in > 24 months were significantly less 
likely to meet accrual targets. 
Duma et al., 
2019 
Identify comorbidities 
that adversely impact 
recruitment of patients 
with breast, colorectal, or 






























-The CTs had the following exclusion criteria: age > 75 
years (6%), history of prior malignancies (86%), 
autoimmune disease with exceptions of vitiligo and 
alopecia (48%), any central nervous system (CNS) 
metastasis (38%), symptomatic CNS metastasis (34%), 
human immunodeficiency virus (31%), hepatitis B or C 
(21%), and atrial fibrillation (20%).  
-Renal and hepatic eligibility criteria were prevalent such 
as creatinine <1.5 of the upper limit of normal (ULN) 
(35%).  
=Compared to targeted therapy CTs, chemotherapy CTs 
were more likely to have exclusion criteria pertaining to 
CNS metastasis and history of other malignancies.  
-Trials sponsored by industry were more likely to have 
liver function exclusion criteria than those with other types 
of sponsors. 
Gerber et al., 
2014 
Determine prevalence of 
prior cancer-related 
exclusion criteria and 
their impact on lung 
cancer CT accrual 
Lung 51 lung cancer 
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=41 (80%) of ECOG -affiliated lung cancer CTs excluded 
prior cancer diagnosis: active cancer (16%), any prior 
cancer (14%), within 5 years (43%), within 2-3 years 
(7%)).  
-Estimated proportion of excluded prior lung cancer 
patients was up to 18% ( >5% for 2/3 of CTs and>10% 
for approximately 1/3 of CTs).  
-Exclusion criteria related to prior cancer treatment were 
present in 20 (39%) of CTs, with 15 (29%) excluding 
chemotherapy or other therapy and 5 (10%) excluding 
both that and radiotherapy. 
Gross et al., 
2005 
Ascertain the effect of 
protocol factors on 
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-Cancer type (early stage) and performance status in 
exclusion criteria were significantly associated with 















Torres et al., 
2020 
Determine if exclusion 
criteria are associated 
with low accrual of older 
adults to cancer CTs 
Multiple 69 Canadian 
Cancer Trials 
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=The following CT factors were associated with lower 
accrual of older adults: start date prior to 2003, breast 
cancer indication, and exclusion criteria related to renal 
dysfunction.  
=Central nervous system CTs were associated with higher 
accrual of older adults.   
Khunger et al., 
2018 
Ascertain the frequency 
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with withdrawal and early 
termination of oncology 
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- Low accrual was the most common reason for early 
termination for all trials.  
-5% of CTs were early terminated, and 3.5% were 
withdrawn. 
- 4% of ICI trials were early terminated, and 1.4% were 
withdrawn.  
- ICI trials were less likely to early terminate compared 
with all other oncology drug trials, but the results were 
not statistically significant.  
- Institution-sponsored trials were significantly more 
likely to early terminate compared with industry 
sponsored trials.  
- Phase II and phase III trials were significantly less 
likely to early terminate compared with phase I trials.  
- The accrual goal was higher for completed trials with a 
median 47 compared with terminated trials with a median 
9. 
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Overall, the total number of eligibility criteria did not 
affect enrollment duration. However, it was significantly 
associated with the enrollment period’s duration in trials 
that had at least 35 patients.  
Korn et al., 
2010 
Examine accrual for 
National Cancer Institute 
(NCI) Cooperative Group 
phase III CTs between 
2000-2007 
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An estimated 22.0% of all adult and pediatric CTs would 
be terminated due to inadequate accrual, with 1.7% 
(2,991) of the total enrolled accrued patients being on 
these CTs. Fewer breast cancer CTs terminate due to 
inadequate accrual. 2 of 42 pediatric trials had poor 
accrual. None of the pediatric nonrandomized  CTs had 
inadequate accrual. There was no significant difference in 
inadequate accrual between CTs that involved an 
investigational new drug and those that did not.   
Lemieux et al., 
2008 
Identify protocol 
characteristics of breast 
cancer CTs associated 
with poor recruitment  
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The following protocol factors were associated with 
better recruitment: no placebo vs. placebo, nonmetastatic 
vs. metastatic, and allowed 12 week or more interval vs. 
less from diagnosis, surgery, or end of previous therapy 
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-Accrual was poorer for Radiation Therapy Oncology 
Group trials than other cooperative groups and for 
multimodality trials that did not primarily include 
systemic treatment.  
-Accrual was better for trials that involved advanced 
disease.  
-CTs involving standard therapy regardless of the 
inclusion of a new therapy had better accrual. 
Massett et al., 
2016 
Determine reasons for 
slow accrual in early 
phase trials sponsored by 
the National Cancer 
Institute  




*11 (8%) were 
pediatric trials 
and 5 (4%) 
I, II Corrective 









-The main reported reasons for slow accrual for phase I 
CTs were safety/toxicity (48%), design/protocol issues 
(42%) and eligibility criteria (41%).  The main reasons 
for phase II CTs were eligibility criteria (35%) and 
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-Lack of accrual (57.5%) was the main reason for trial 
failure  
-Significantly more trials failed with each consecutive 
time period (11.8% before 2007, 34% in 2007-2008, and 
39.5% in 2009-2012).  
-Predictors of failure were surgical comparator, 
government sponsorship, safety endpoint, and studies 
starting after 2006 via univariate analysis.  
-Via multivariate analysis, predictor of failure was 
surgical trials, and predictor of trial success was 
behavioral trials.  
Paul et al., 
2019 
Determine predictors of 
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-63% of trials reported sufficient accrual.  
-There was no significant difference in adequate accrual 
between urological and nonurological trials. 
-Kidney cancer trials accrued the best whereas bladder 
cancer trials accrued the worst. 
-Compared to government funded trials, industry 
sponsored trials were significantly more likely to attain 
adequate accrual.  
-No other factors (e.g.  age group, nonrandomized vs 
randomized,  intervention model, therapeutic vs 
nontherapeutic, masking vs open label, primary purpose, 
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-The fastest accruing CTs were those that had the 
following characteristics: multinational, breast cancer 
indication, industry sponsorship, and equivalency.   
-There were no significant differences in accrual time 
between placebo and non-placebo CTs and those CTs 
conducted in the United States versus Europe.  
Stensland et 
al., 2014 
Evaluate study factors 
associated with trials that 
fail to complete 
Multiple 7776 adult 
interventional 
cancer trials 






-The most common reason for CTs to fail to complete 
was poor accrual (39%). 
-The following trials were more likely to not complete: 
---Single center versus multicenter trials 
---Industry-sponsored versus federally funded trials 
-Trials performed outside of the United States or both 
within and outside of the United States were more likely 





Manuscript #3  
 
Predictors of Early Termination of Pediatric Oncology Clinical Trials Due to Poor 
Accrual: An Exploratory Analysis 






Predictors of Early Termination of Pediatric Oncology Clinical Trials Due to Poor 
Accrual: An Exploratory Analysis 
 
Abstract 
Background: Poor accrual is a significant barrier to the completion of pediatric oncology 
clinical trials. Early terminated or prolonged trials have substantial financial implications 
and hinder the availability of new effective pediatric cancer therapies in a timely manner. 
The purposes of this study were to 1) describe patterns in the presence of variables and 
completeness of data entry for variables in the ClinicalTrials.gov database over time for 
pediatric oncology trials and 2) investigate trial-related factors that may affect early 
termination of pediatric oncology clinical trials due to low accrual. 
Procedure: ClinicalTrials.gov data were extracted from Aggregate Analysis of 
ClinicalTrials.gov (AACT). Descriptive statistics and multiple logistic regression were 
used to analyze the data. 
Results: The number of variables increased with each subsequent period, except the most 
recent period (150, 159, 160 and 139, respectively). Of the 160 examined variables, 129 
(81%) variables had 100% of applicable data in each period. None of the following 
clinical trial characteristics were associated with or predictive of early termination of 
pediatric oncology trials due to low accrual: enrollment, primary purpose, intervention 
type, phase, interventional model, allocation, arm type, number of arms, masking, 
primary end points, number of primary outcomes, sponsor, number of participating 
facilities, and primary disease. However, odds for studies to terminate early were 3.9 
times higher for those that used a data and safety monitoring committee compared to 




Conclusions: Knowledge of trial-level factors that may affect accrual and completion of 
those trials may enable researchers to strategically design trials in a manner that 





Predictors of Early Termination of Pediatric Oncology Clinical Trials Due to Poor 
Accrual: An Exploratory Analysis 
 
Introduction 
Cancer is the second-leading cause of death among children in the United States, 
exceeded only by injuries.1 In 2020, it was predicted that 11,050 children ages 0-14 years 
old would be diagnosed with cancer, and 1,190 children in the same age group would die 
from cancer.1 Besides death, ramifications of childhood cancer include long-term 
complications from anticancer therapies such as secondary malignancies and financial 
hardships for survivors and their families.2,3 As of 2019, only 34 drugs had been 
approved by the United States Food and Drug Administration (FDA) for the treatment of 
pediatric cancers.4 New effective anticancer therapies are necessary as evidenced by 
cancer remaining a leading cause of death for children. The following types of cancers 
account for almost 82% of childhood cancer deaths: brain (30.0%), leukemia (24.8%), 
bone and articular (10.1%), endocrine (9.0%), and mesothelial/soft tissue (7.7%).5 
Clinical trials afford new effective therapies for children with cancer by 
establishing the safety and efficacy/effectiveness of drug discoveries. Alongside the need 
for new effective cancer therapies for children, the number of pediatric oncology clinical 
trials and their associated costs have substantially increased. According to the 
ClinicalTrials.gov database, 32 pediatric oncology clinical trials were initiated in 2010 
whereas this number grew to 137 in 2019.6 Clinical trials for FDA-approved oncology 
drugs in 2015-2017 had a median cost of $37.1 million per trial (interquartile range = 




Poor accrual is a significant barrier to the completion of pediatric oncology 
clinical trials. For a study’s findings to be valid, an adequate sample size is required.8 
Approximately 60% of children with cancer are treated in clinical trials.9 Consequently, 
pediatric oncology clinical trials that are terminated early or prolonged due to poor 
accrual adversely impact treatment outcomes; in addition, early termination or 
prolongation of trials negatively affects the financial well-being of trial sponsors such as 
governmental organizations, academic institutions and the pharmaceutical industry, along 
with that of institutions participating in the trials.10 Most notably, early terminated or 
prolonged trials hinder the release of new effective pediatric cancer therapies in a timely 
manner.  
The literature demonstrates that factors impacting accrual and completion of adult 
oncology clinical trials operate at the trial, individual, interpersonal, organizational, 
community, and policy levels.11-16 Trial level factors include the following: sponsor, trial 
development time, number and location of participating institutions, sample size, 
competing trials, time of trial opening, fast-track status, type of cancer, incidence of the 
targeted cancer, and presence of metastases.11,17-27 Other trial level factors include type of 
treatment, eligibility criteria, randomization, required procedures and their timing, use of 
a placebo, and phase of study.11,18-26,28-32 However, a dearth of research exists about trial 
level factors that may affect accrual in pediatric oncology clinical trials. Trial level 
factors may differ between trials for pediatric and adult populations because these 




As a result of a growing demand for transparency regarding clinical trials by the 
government and public to facilitate drug development and safety, many sponsors are 
required by federal regulations to register their trials on ClinicalTrials.gov.34 Registration 
is required for clinical trials that involve an FDA investigational new drug application, 
have at least one participating site in the United States, or involve a drug, biological, or 
device produced in the United States and exported elsewhere.35,36 Before the 
ClinicalTrials.gov database became accessible in 2000, researchers relied upon available 
data from a single trial or multiple trials within a single institution to investigate trial-
level factors. ClinicalTrials.gov now allows researchers to investigate clinical trials as an 
enterprise. However, changes in regulations over the last two decades resulted in 
discrepancies in the type and completeness of data that investigators submitted into the 
database during that time frame.37 As a result, the amount of available data differs among 
variables such as eligibility criteria and sample size and across different time periods. 
To address the previously discussed gaps in knowledge of accrual and early 
termination of pediatric oncology trials, this study aimed to: 1) describe patterns in the 
presence of variables and completeness of data entry for variables in the 
ClinicalTrials.gov database over time; and 2) investigate trial-related factors that may 
affect early termination of pediatric oncology clinical trials due to low accrual.  
Theoretical Framework 
Bennette et al’s11 conceptual model of trial-level factors associated with low trial 
accrual guided variable selection, data analysis and organization of results. The model 




accrual: background, disease-related, treatment-related, and trial design. Background 
factors include factors such as greater competition from other trials and less state-level 
coverage of clinical trial costs. Disease-related factors include factors such as less 
advanced disease, solid tumor setting, less compelling scientific rationale, and lower 
annual incidence of the eligible population. Treatment-related factors include factors such 
as treatment in trials that are greatly different from standard of care, research question not 
relevant to clinical practice, patient or provider preference for a particular treatment, 
radiotherapy or surgical treatment, not an investigational new agent, more expensive 
treatment, higher risk for toxicity, multimodality, and less compelling scientific rationale. 
Trial design factors include factors such as strict or many eligibility criteria, randomized 
design, placebo-controlled arm, greater trial complexity, and longer required follow-up. 
Methods 
To examine possible trial-related predictors of early termination of pediatric 
oncology clinical trials due to low accrual, the authors utilized ClinicalTrials.gov data 
which were extracted from Aggregate Analysis of ClinicalTrials.gov (AACT). The 
researchers chose ClinicalTrials.gov because it is the largest and most comprehensive 
database of clinical trials in the world.38 
ClinicalTrials.gov Dataset Description 
Maintained by the National Library of Medicine (NLM), ClinicalTrials.gov is a 
database that includes information about clinical trials and other types of studies for 
diverse illnesses, including cancer. This database, which is accessible by the public, 




216 countries. Sponsors or primary investigators provide both, the initial information and 
periodic updates of the clinical trials.6 
The National Institutes of Health (NIH) created ClinicalTrials.gov as a registry of 
clinical trials that examine investigational drugs’ effectiveness for serious illnesses due a 
mandate by the Food and Drug Administration Modernization Act of 1997 (FDAMA). In 
2000, ClinicalTrials.gov became accessible to the public. Subsequently, the Amendments 
Act of 2007 (FDAAA) required the database’s expansion to include other types of 
clinical trials and additional information about the trials, including their results. The law 
also instituted penalties for failure to provide the required information. In 2016, the Final 
Rule for Clinical Trials Registration and Results Information Submission (42 CFR Part 
11) further expanded the required information for clinical trials. Thus, because of laws, 
the number of registered trials and amount of available information for these trials have 
increased over time. In addition, over the years more sponsors and investigators have 
provided their trial data due to other policies.36,37 For example, in 2005 the International 
Committee of Medical Journal Editors instituted the requirement of clinical trial 
registration for publication.39 
Aggregate Analysis of ClinicalTrials.gov (AACT) Dataset Description 
Aggregate Analysis of ClinicalTrials.gov (AACT) is a database that contains all 
ClinicalTrials.gov data related to registered protocols and their results. Every day the data 
in ClinicalTrial.gov are uploaded to AACT, a relational database.40 The AACT database 
was chosen for this study because it allows ClinicalTrials.gov data to be more easily 




the ClinicalTrials.gov website. The files on ClinicalTrials.gov are very large zipped files, 
each containing a large number of sub-files in XML format that cannot easily be 
imported into SPSS without use of XML syntax and/or purchase of an XML to SPSS 
converter. In contrast, files in the AACT database have been converted to .txt, 
simplifying and reducing steps for the user.          
Data Analysis 
 SPSS Version 25 (Armonk, NY: IBM Corp, 2017) was used to perform analyses 
of selected variables from the AACT dataset. The aims were to describe patterns in the 
presence of variables and completeness of data entry for variables in the 
ClinicalTrials.gov database over time and 2) investigate trial-related factors that may 
affect early termination of pediatric oncology clinical trials due to low accrual. For both 
aims, frequency distributions for all variables are reported in tables. For Aim 2, Chi-
square statistics were obtained to determine whether a relationship between the potential 
predictor variables (enrollment, primary purpose, intervention type, phase, interventional 
model, allocation, arm type, number of arms, masking, primary end points, number of 
primary outcomes, sponsor, number of participating facilities, primary disease, data 
monitoring committee) and early termination of clinical trial due to low accrual exists. 
Frequencies and percentages are reported. In addition, multiple logistic regression was 
performed. Forward stepwise and forced entry multiple logistic regression were used to 
add potential predictors sequentially into the model based on a significance level α of < 






Characteristics of Clinical Trials 
A total of 474 pediatric interventional oncology trials were identified in the 
AACT database. Of the different time periods examined in this study, most pediatric 
oncology trials (n = 222) were initiated during 2008 – 2017. Most of the trials did not 
specify any participating institutions within the United States (n = 258) and/or had a 
status other than completed or terminated/withdrawn (n = 210). Of the total pediatric 
interventional oncology trials, 105 were trials conducted in the United States that were 
either completed (n = 87, 83%) or terminated/withdrawn due to poor accrual (n = 18, 
17%). Most of these trials (n = 77, 73%) enrolled 100 or fewer subjects. Over half of the 
trials (n = 62, 59%) had a primary aim to test a treatment, with drugs being the most 
frequent type of intervention (n = 48, 46%). The most common phase of trial was II (n = 
27, 26%), and 49 (47%) trials had a single group study design. Forty trials (38%) 
involved randomization. Most trials had two arms (n = 41, 39%), with the majority of 
trials (n = 73, 70%) having an experimental arm versus an active, sham, placebo, or no 
intervention control arm. Most trials (n = 74, 70%) had no masking, i.e., neither study 
participants nor raters obtaining assessments were blinded to the treatment assignment. 
Almost half (n = 50, 48%) were sponsored internally by universities and hospitals. Even 
though leukemia was the most frequent primary disease (n = 25, 24%), trials (n = 34, 
32%) often included patients with multiple types of cancer. The majority of trials had > 1 





Trials with a Given Variable Completed within Four Time Periods 
The researchers aimed to describe patterns in the presence of variables and 
completeness of data entry for variables in the ClinicalTrials.gov database over time. 
Over time, new regulations mandated additional variables be captured within 
ClinicalTrials.gov. The researchers examined the frequency and proportion of pediatric 
oncology clinical trials with a given variable completed within four periods defined by 
new regulations affecting data entry in ClinicalTrials.gov (see Table 1). The number of 
initiated trials increased with each subsequent time period (n = 27 initiated before 
21Nov1997 [Period I]; n = 120 between 21Nov1997 and 31Aug2008 [Period II]; n = 222 
between 01Sep2008 and 17Apr2017 [Period III]), except the most recent time period (n = 
98 between 18Apr2017 and 01May2020 [Period IV]), when the data were retrieved from 
ClinicalTrials.gov. In addition, the number of variables increased with each subsequent 
period, except the most recent period (150, 159, 160 and 139, respectively). Of the 160 
examined variables, 129 (81%) variables had 100% of applicable data in each period. If a 
variable was included in a period, that variable was not necessarily included in a 
subsequent period, e.g. number of related serious events and sample size included in 
analysis for each outcome for each study group. The third period had the most complete 
data, with 99.6% compared with 84.4% in first period, 85.5% in the second, and 83.2% in 
the fourth period. The most incomplete data in the fourth period pertain to final analyses 
and results, e.g. sample size included in analysis for each outcome for each study group, 
number of withdrawals/drops, and number of related serious events.  






 No statistically significant associations between clinical trial characteristics and 
early termination/withdrawal of pediatric oncology trials were observed (Table 4) except 
for use of a data and safety monitoring committee. Though p is not below 0.05, the odds 
of early termination/withdrawal were almost 4 times higher among trials with a data 
monitoring committee than those without one (OR = 3.9, p = 0.05). Also, the odds of 
termination/withdrawal of clinical trials with one primary outcome were almost 2 times 
higher than those with two or more primary outcomes (OR = 1.73, p = .390). Also, 
though not statistically significant, differences in proportions of enrollment and early 
terminated/withdrawn trials were observed (93% vs 7%, p = .29). These findings should 
be further investigated. 
Predictors of Early Termination of Pediatric Oncology Clinical Trials Due to Low 
Accrual 
 
 Multiple logistic regression modeling was used to examine whether 
characteristics of clinical trials were predictive of early termination of pediatric oncology 
trials due to low accrual (see Table 5) when combined. None of the clinical trial 
characteristics were predictive of early termination of pediatric oncology trials due to low 
accrual in these data. 
Discussion 
 This study aimed to 1) describe patterns of the presence of variables and 
completeness of data entry for variables in the ClinicalTrials.gov database over time and 
2) investigate trial-related factors that may affect early termination of pediatric oncology 




pediatric oncology patients, the number of clinical trials that can be conducted is 
constrained by limited financial resources and willing participants. Therefore, 
identification of trial-level factors associated with poor accrual is crucial, to minimize the 
expenditure of valuable resources for the development and conduct of trials with a high 
likelihood of failing to complete.17 
Patterns of Presence of Variables and Completeness of Data Entry for Variables in 
ClinicalTrials.gov Database 
 
 Patterns of the presence of variables and completeness of data entry for variables 
in the ClinicalTrials.gov database differed over time. ClinicalTrials.gov did not exist 
prior to 1997 so available data about initiated trials during this period were extremely 
limited and entered retrospectively. The most recent period (18Apr2017-01May2020) had 
fewer initiated clinical trials than the previous two periods which is due to this time 
period consisting of only three years as opposed to the previous two periods which each 
consisted of approximately 10 years. The number of required variables increased each 
subsequent period until the third period due to increased regulations and policies 
mandating increased transparency of clinical trials. The decline in completed data in the 
most recent period is likely due to clinical trials initiated during this period still ongoing. 
Information for many variables, such as number of adverse events and sample size 
included in analysis for each outcome for each study group, is not available until after the 
completion of a trial. With the continued growth in number of clinical trials and increased 
regulations to facilitate transparency of clinical trials, ClinicalTrials.gov may become a 




Predictors of Early Termination of Pediatric Oncology Clinical Trials Due to Low 
Accrual 
 
Unexpectedly, none of the examined trial characteristics were found to be 
predictors of early termination of pediatric oncology trials: enrollment, primary purpose, 
intervention type, phase, interventional study model, allocation, arm type, number of 
arms, masking, primary end points, number of primary outcomes, sponsor, number of 
participating facilities, primary disease, and data and safety monitoring committee. These 
results are contrary to the literature that demonstrated trial-level factors impact accrual 
and completion of adult oncology clinical trials.11,17-32 The difference in results compared 
to available adult trials may be due to small number of examined pediatric oncology 
clinical trials which limits testing power. Also, the combination of several categories of 
trial characteristics within variables necessary for analyses due to small frequencies in 
some categories was a limiting factor. For example, the original plan was to analyze each 
of the following types of interventions as has been done in studies of adult oncology 
clinical trials: drugs, behavioral, biological, combination product, device, diagnostic test, 
dietary supplement, genetic, procedure, and radiation. However, due to the small number 
of trials in each category, all intervention types except drugs had to be combined for 
testing. Even with combining categories, some of the resulting groups remained small 
due to the small overall sample size as well as the imbalance between completed and 
early terminated trials. The likelihood of type II errors increases with small groups, 





 This study has multiple strengths. Predictors of early termination of oncology 
clinical trials due to poor accrual have been understudied in the pediatric population. 
ClinicalTrials.gov is the largest database of clinical trials, thus this study’s results are 
more generalizable than if the study had a sample consisting of trials conducted at a 
single or few institutions. Also, this study analyzed clinical trials sponsored by both 
cooperative groups and pharmaceutical companies as both operate differently. The 
cooperative group program is part of a governmental agency, the National Cancer 
Institute, and pharmaceutical companies are for-profit organizations. 
Limitations 
 This study has limitations, several of which pertain to the ClinicalTrials.gov 
database. Existing legislation does not require all types of clinical trials, such as phase I 
trials, to be registered on ClinicalTrials.gov.36 In addition, data for all examined variables 
are not present as the data are currently and/or were previously not required.35 The first 
aim of this study was to describe patterns of the presence of variables and completeness 
of data entry for variables in the ClinicalTrials.gov database over time. Results could 
differ based on the cut-off dates for time periods as it takes time for laws and policies to 
be fully implemented.19 The second aim of this study was to investigate trial-related 
factors that may affect early termination of pediatric oncology clinical trials due to low 
accrual. Results for the study’s second aim could differ based on the timing of the study 
because sponsors and principal investigators can retrospectively update information in 
ClinicalTrials.gov. Also, some of the groups within variables such as type of 




legislation for required data submission to ClinicalTrials.gov and enforcement of the 
current and future legislature could improve analyses. The use of only one clinical trials 
database may have introduced bias since data in ClinicalTrials.gov may be inaccurate.25 
Incorporating the use of another large database such as the European Union Drug 
Regulating Authorities Clinical Trials Database (EudraCT) may lessen bias in future 
research.  
Limitations exist with the dependent variable of early termination of clinical trials 
due to inadequate accrual. The imbalance between the numbers of completed trials and 
trials terminated/withdrawn due to poor accrual is a limitation because it is more difficult 
to identify predictors since the terminated/withdrawn group is so small. Reason for the 
termination or withdrawal of a clinical trial is not a required field by ClinicalTrials.gov, 
thereby possibly introducing selection bias.20 Also, all cases of early termination due to 
inadequate accrual may not have been captured for the analysis. For example, sponsors 
may have reported the reasons for termination or withdrawal as “cancellation of trial by 
sponsor” or “inadequate budget.” Both of these reasons may have been related to poor 
accrual. Also, often there are multiple reasons for a trial to be terminated or withdrawn.27 
For example, a trial may be terminated for both poor accrual and inadequate budget and 
yet only one reason is entered into ClinicalTrials.gov. 
Other limitations are related to confounding variables. The effects of variables at 
the individual, interpersonal, organizational, community and policy levels were not 
addressed in this study. Furthermore, this study did not assess trial-level factors that other 




due to inadequate accrual, such as disease incidence, eligibility criteria, and tissue 
testing.11,41 
Implications 
This study has several implications. Identification of modifiable trial-level factors that are 
associated with inadequate accrual may enable future trials to be designed in a manner 
that facilitates accrual and their completion.11,17 Meanwhile, healthcare providers can 
provide patient education about non-modifiable trial-level factors to possibly increase 
acceptance and trial participation.17,22 Sponsors and institutions can prioritize clinical 
trials that have trial-level factors that are associated with accrual and trial completion. If 
sponsors and institutions develop and/or select trials with trial-level factors that are 
associated with inadequate accrual or early termination, they will be aware in advance 
that increased resources and interventions will likely be required for successful trial 
completion.11,41 Sponsors should ensure the reason for early study terminations is 
documented in ClinicalTrials.gov so these data are available for future research 
endeavors about trial-level factors associated with early termination of clinical trials. 
Future Research 
Future research is needed pertaining to trial-level factors associated with early 
termination of pediatric oncology clinical trials due to inadequate accrual. Research can 
advance study findings by including pediatric oncology clinical trials conducted 
throughout the world, rather than focusing on just those conducted within the United 
States. Also, variables such as eligibility criteria in the ClinicalTrials.gov that were not 




oncology clinical trials due to inadequate accrual, such as eligibility criteria, should be 
considered for future study. Finally, research can be conducted to determine if 
interventions such as patient education regarding non-modifiable trial-level factors can 
improve accrual and completion of pediatric oncology clinical trials.  
Conclusions 
New, effective anticancer therapies for children are necessary as evidenced by cancer 
being the second-leading cause of death among children in the United States. Yet, limited 
financial and human resources exist for the conduct of clinical trials. Therefore, sponsors 
and institutions must develop and prioritize clinical trials that have a high likelihood of 
accruing and completing. The identification of trial-level factors that are associated with 
accrual and/or trial completion is crucial for this to occur. This study identified patterns 
in the presence of variables and completeness of data entry for variables in the 
ClinicalTrials.gov database over time. It also investigated trial-related factors that may 
affect early termination of pediatric oncology clinical trials due to low accrual.  Findings 
of trial characteristics included in this study suggest they are not predictive of early 
termination of pediatric oncology trials, possibly due to the small number of available 
trials. However, the authors did not include evaluation of trial inclusion/exclusion criteria 
and trial complexity because these variables were not readily available in the database, 
and these factors may be important drivers of failure to accrue/complete clinical trials 
based on the existing literature. Future studies may evaluate these factors and examine a 




accrual and/or pediatric oncology trial completion and strategies to address the trial-level 
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TABLE 1 Frequency and proportion of trials with a given variable completed within four 
periods 













 I II III IV 
Sample size at baseline 
for each study group 
4 (14.8%) 23 (19.2%) 30 (13.5%)  0 (0%) 
Baseline type of units of 
measure of sample 
27 (100%) 120 (100%) 222 (100%) 98 (100%) 
Baseline parameter for 
units of measure of 
sample 
4 (14.8%) 23 (19.2%) 29 (13.1%) 0 (0%) 
Brief description of 
study 
27 (100%) 120 (100%) 222 (100%) 98 (100%) 
Intervention MeSH 
terms  
27 (100%) 120 (100%) 222 (100%) 98 (100%) 
Number of facilities 27 (100%) 113 (94.2) 190 (85.6%) 89 (90.8%) 
Number of related non-
serious events 
4 (14.8%) 23 (19.2%) 30 (13.5%) 0 (0%) 
Number of related 
serious events 
4 (14.8%) 23 (19.2%) 30 (13.5%) 0 (0%) 
Year of registration 27 (100%) 120 (100%) 222 (100%) 98 (100%) 
Number of months 
between start date and 
primary completion 
date 
15 (55.6%) 79 (65.8%) 144 (64.9%) 10 (10.2%) 
Results reported 27 (100%) 120 (100%) 222 (100%) 98 (100%) 
Number of months 
between primary 
completion date and 
first received results 
date 
4 (14.8%) 23 (19.2%) 30 (13.5%) 0 (100%) 
Study has at least one 
facility in USA 
27 (100%) 120 (100%) 222 (100%) 98 (100%) 
Study has just one 
facility 
27 (100%) 120 (100%) 222 (100%) 98 (100%) 
Minimum age 
converted to an integer 
7 (25.9%) 54 (45.0%) 161 (72.5%) 77 (78.6%) 
Maximum age 
converted to an integer 
27 (100%) 120 (100%) 222 (100%) 98 (100%) 
Part of minimum age 
info that specifies units 




Part of maximum age 
info that specifies units 
27 (100%) 120 (100%) 222 (100%) 98 (100%) 
Number of primary 
outcomes 
15 (55.6%) 98 (81.7%) 220 (99.1%) 98 (100%) 
Number of secondary 
outcomes 
9 (33.3%) 59 (49.2%) 158 (71.2%) 65 (66.3%) 
Number of other 
outcomes 
0 (0%) 0 (0%) 9 (4.1%) 7 (7.1%) 
Condition MeSH terms 27 (100%) 120 (100%) 222 (100%) 98 (100%) 
Conditions under study 27 (100%) 120 (100%) 222 (100%) 98 (100%) 
Country where facility 
located 
27 (100%) 120 (100%) 222 (100%) 98 (100%) 
Type of arm 27 (100%) 120 (100%) 222 (100%) 98 (100%) 
Date when results were 
first received 
27 (100%) 120 (100%) 222 (100%) 98 (100%) 
Descriptions of design 
groups 
27 (100%) 120 (100%) 222 (100%) 98 (100%) 
Are results primary or 
secondary outcomes 
27 (100%) 120 (100%) 222 (100%) 98 (100%) 
Measure used 27 (100%) 120 (100%) 222 (100%) 98 (100%) 
Time frame in which 
events were reported 
27 (100%) 120 (100%) 222 (100%) 98 (100%) 
Description of design 
outcomes 
27 (100%) 120 (100%) 222 (100%) 98 (100%) 
Type of allocation 27 (100%) 120 (100%) 222 (100%) 98 (100%) 
Interventional model 27 (100%) 120 (100%) 222 (100%) 98 (100%) 
Observational model 27 (100%) 120 (100%) 222 (100%) 98 (100%) 
Primary purpose 27 (100%) 120 (100%) 222 (100%) 98 (100%) 
Observational timing 27 (100%) 120 (100%) 222 (100%) 98 (100%) 
Type of masking 27 (100%) 120 (100%) 222 (100%) 98 (100%) 
Description of 
intervention 
27 (100%) 120 (100%) 222 (100%) 98 (100%) 
Was subject masked? 27 (100%) 120 (100%) 222 (100%) 98 (100%) 
Was caregiver masked? 27 (100%) 120 (100%) 222 (100%) 98 (100%) 
Was investigator 
masked? 
27 (100%) 120 (100%) 222 (100%) 98 (100%) 
Was outcome accessor 
masked? 
27 (100%) 120 (100%) 222 (100%) 98 (100%) 
Detailed description of 
protocol 
27 (100%) 120 (100%) 222 (100%) 98 (100%) 
Uploaded documents 27 (100%) 120 (100%) 222 (100%) 98 (100%) 
Link for study-related 
documents 




Period of drops and 
withdrawals 
27 (100%) 120 (100%) 222 (100%) 98 (100%) 
Reasons for drops or 
withdrawals 
27 (100%) 120 (100%) 222 (100%) 98 (100%) 
Number of drops or 
withdrawals 
1 (3.7%) 20 (16.7%) 26 (11.7%) 0 (0%) 
Sampling method 27 (100%) 120 (100%) 222 (100%) 98 (100%) 
Gender 27 (100%) 120 (100%) 222 (100%) 98 (100%) 
Minimum age 27 (100%) 120 (100%) 222 (100%) 98 (100%) 
Maximum age 27 (100%) 120 (100%) 222 (100%) 98 (100%) 
Were healthy volunteers 
eligible? 
27 (100%) 120 (100%) 222 (100%) 98 (100%) 
Brief description of 
eligible patients 
27 (100%) 120 (100%) 222 (100%) 98 (100%) 
Inclusion and exclusion 
criteria 
27 (100%) 120 (100%) 222 (100%) 98 (100%) 
Study status 27 (100%) 120 (100%) 222 (100%) 98 (100%) 
Name of facility 27 (100%) 120 (100%) 222 (100%) 98 (100%) 
Facility’s city 27 (100%) 120 (100%) 222 (100%) 98 (100%) 
Facility’s state 27 (100%) 120 (100%) 222 (100%) 98 (100%) 
Facility’s zip code 27(100%) 120 (100%) 222 (100%) 98 (100%) 
Facility’s country 27 (100%) 120 (100%) 222 (100%) 98 (100%) 
Terms or phrases 
synonymous with 
intervention 
27 (100%) 120 (100%) 222 (100%) 98 (100%) 
Intervention or 
exposure 
27 (100%) 120 (100%) 222 (100%) 98 (100%) 
Name of specific 
intervention 
27 (100%) 120 (100%) 222 (100%) 98 (100%) 
Description of 
intervention 
27 (100%) 120 (100%) 222 (100%) 98 (100%) 
URL for intervention 27 (100%) 120 (100%) 222 (100%) 98 (100%) 
Description of URL for 
study 
27 (100%) 120 (100%) 222 (100%) 98 (100%) 
Period of study when 
study was not 
completed 
27 (100%) 120 (100%) 222 (100%) 98 (100%) 
Outcome count 4 (14.8%) 23 (19.2%) 30 (13.5%) 0 (0%) 
Type of non-inferiority 27 (100%) 120 (100%) 222 (100%) 98 (100%) 
Description of non-
inferiority 
27 (100%) 120 (100%) 222 (100%) 98 (100%) 
Parameter type of 
outcome 




Parameter value of 
outcome 
0 (0%) 6 (5.0%) 9 (4.1%) 0 (0%) 
p value modifier 27 (100%) 120 (100%) 222 (100%) 98 (100%) 
p value 0 (0%) 7 (5.8%) 9 (4.1%) 0 (0%) 
One- or two-sided 
confidence level 
27 (100%) 120 (100%) 222 (100%) 98 (100%) 
Confidence interval 0 (0%) 5 (4.2%) 8 (3.6%) 0 (100%) 
Confidence interval 
lower limit 
0 (0%) 3 (2.5%) 8 (3.6%) 0 (0%) 
Confidence interval 
higher limit 
0 (0%) 4 (3.3%) 8 (3.6%) 0 (0%) 
p value description 27 (100%) 120 (100%) 222 (100%) 98 (100%) 
Statistical method 27 (100%) 120 (100%) 222 (100%) 98 (100%) 
Statistical method 
description 
27 (100%) 120 (100%) 222 (100%) 98 (100%) 
Description of estimates 27 (100%) 120 (100%) 222 (100%) 98 (100%) 
Description of groups 27 (100%) 120 (100%) 222 (100%) 98 (100%) 
Units for outcome 27 (100%) 120 (100%) 222 (100%) 98 (100%) 
Sample size included in 
analysis for each 
outcome for each study 
group 
4 (14.8%) 23 (19.2%) 30 (13.5%) 0 (0%) 
Title of outcome 
measurement 
27 (100%) 120 (100%) 222 (100%) 98 (100%) 
Description of outcome 
measurement 
27 (100%) 120 (100%) 222 (100%) 98 (100%) 
Units of outcome 
measurement 
27 (100%) 120 (100%) 222 (100%) 98 (100%) 
Parameter type of 
outcome measurement 
27 (100%) 120 (100%) 222 (100%) 98 (100%) 
Parameter value of 
outcome measurement 
4 (14.8%) 23 (19.2%) 27 (12.2%) 0 (0%) 
Dispersion type of 
outcome measurement 
27 (100%) 120 (100%) 222 (100%) 98 (100%) 
Dispersion value of 
outcome measurement 
0 (0%) 7 (5.8%) 11 (5.0%) 0 (0%) 
Lower limit of outcome 
measurement 
0 (0%) 6 (5.0%) 5 (2.3%) 0 (0%) 
Upper limit of outcome 
measurement 
0 (0%) 6 (5.0%) 5 (2.3%) 0 (0%) 
Outcome type 27 (100%) 120 (100%) 222 (100%) 98 (100%) 
Outcome title 27 (100%) 120 (100%) 222 (100%) 98 (100%) 




Timeframe of outcome 27 (100%) 120 (100%) 222 (100%) 98 (100%) 
Outcome population 27 (100%) 120 (100%) 222 (100%) 98 (100%) 
Units of outcome 27 (100%) 120 (100%) 222 (100%) 98 (100%) 
Dispersion type 
outcome 
27 (100%) 120 (100%) 222 (100%) 98 (100%) 
Parameter type of 
outcome 
27 (100%) 120 (100%) 222 (100%) 98 (100%) 
Details of recruitment 27 (100%) 120 (100%) 222 (100%) 98 (100%) 
Details of pre-
assignment 
27 (100%) 120 (100%) 222 (100%) 98 (100%) 
Date of adverse event 27 (100%) 120 (100%) 222 (100%) 98 (100%) 
Time frame in which 
adverse events were 
reported 
27 (100%) 120 (100%) 222 (100%) 98 (100%) 
Type of adverse event 27 (100%) 120 (100%) 222 (100%) 98 (100%) 
Where did adverse 
event terminology come 
from 
27 (100%) 120 (100%) 222 (100%) 98 (100%) 
Type of adverse event 
assessment 
27 (100%) 120 (100%) 222 (100%) 98 (100%) 
Number of subjects 
with adverse events 
4 (14.8%) 23 (19.2%) 30 (13.5%) 0 (0%) 
Number of subjects at 
risk for adverse events 
4 (14.8%) 23 (19.2%) 30 (13.5%) 0 (0%) 
Description of adverse 
event 
27 (100%) 120 (100%) 222 (100%) 98 (100%) 
Number of adverse 
events 
0 (0%) 9 (7.5%) 10 (4.5%) 0 (0%) 
Organ system affected 
by adverse event 
27(100%) 120 (100%) 222 (100%) 98 (100%) 
Terminology used to 
describe adverse events 
27 (100%) 120 (100%) 222 (100%) 98 (100%) 
Frequency threshold of 
adverse event 
4 (14.8%) 23 (19.2%) 30 (13.5%) 0 (0%) 
Type of result reported 27 (100%) 120 (100%) 222 (100%) 98 (100%) 
Title of group for which 
results were reported 
27 (100%) 120 (100%) 222 (100%) 98 (100%) 
Description of group for 
which results reported 
27 (100%) 120 (100%) 222 (100%) 98 (100%) 
Type of sponsor 27 (100%) 120 (100%) 222 (100%) 98 (100%) 
Was sponsor the lead or 
collaborator?  
27 (100%) 120 (100%) 222 (100%) 98 (100%) 




Date study was first 
submitted to 
ClinicalTrials.gov 
27 (100%) 120 (100%) 222 (100%) 98 (100%) 
Date results were first 
submitted to 
ClinicalTrials.gov 
27 (100%) 120 (100%) 222 (100%) 98 (100%) 
Date of last submission 
to ClinicalTrials.gov 
27 (100%) 120 (100%) 222 (100%) 98 (100%) 
Submission date of 
version of record that 
met quality control 
criteria 
27 (100%) 120 (100%) 222 (100%) 98 (100%) 
Date that submission 
was made public on 
ClinicalTrials.gov 
27 (100%) 120 (100%) 222 (100%) 98 (100%) 
Is study first posted date 
an estimate or actual 
date 
27 (100%) 120 (100%) 222 (100%) 98 (100%) 
Is results first posted 
date an estimate or 
actual date 
27 (100%) 120 (100%) 222 (100%) 98 (100%) 
Is last update posted 
date an estimate or 
actual date 
27 (100%) 120 (100%) 222 (100%) 98 (100%) 
Date study started 27 (100%) 120 (100%) 222 (100%) 98 (100%) 
Is start date an estimate 
or the actual date? 
27 (100%) 120 (100%) 222 (100%) 98 (100%) 
Study completion date 27 (100%) 120 (100%) 222 (100%) 98 (100%) 
Is completion date an 
estimate or the actual 
date? 
27 (100%) 120 (100%) 222 (100%) 98 (100%) 
Primary completion 
date 
27 (100%) 120 (100%) 222 (100%) 98 (100%) 
Is primary completion 
date an estimate or the 
actual date? 
27 (100%) 120 (100%) 222 (100%) 98 (100%) 
Type of study 27 (100%) 120 (100%) 222 (100%) 98 (100%) 
Acronym for study 
name 
27 (100%) 120 (100%) 222 (100%) 98 (100%) 
Brief title of study 27 (100%) 120 (100%) 222 (100%) 98 (100%) 
Official title of study 27 (100%) 120 (100%) 222 (100%) 98 (100%) 
Overall status of study 27 (100%) 120 (100%) 222 (100%) 98 (100%) 




Last reported status of 
study 
27 (100%) 120 (100%) 222 (100%) 98 (100%) 
Phase of trial 27 (100%) 120 (100%) 222 (100%) 98 (100%) 
Actual or anticipated 
enrollment number 
25 (92.6%) 108 (90.0%) 222 (100%) 98 (100%) 
Is enrollment number 
actual or anticipated 
number 
27 (100%) 120 (100%) 222 (100%) 98 (100%) 
Source of study data 27 (100%) 120 (100%) 222 (100%) 98 (100%) 
Number of arms 9 (33.3%) 57 (47.5%) 162 (73.0%) 73 (74.5%) 
Number of groups 1 (3.7%) 14 (11.7%) 30 (13.5%) 13 (13.3%) 
Does study have 
expanded access 
27 (100%) 120 (100%) 222 (100%) 98 (100%) 
Does study have a data 
monitoring committee 
27 (100%) 120 (100%) 222 (100%) 98 (100%) 
Does study involve a 
FDA-regulated drug 
27 (100%) 120 (100%) 222 (100%) 98 (100%) 
Does study involve a 
FDA-regulated device 
27 (100%) 120 (100%) 222 (100%) 98 (100%) 
Product manufactured 
in and exported from 
US 
27 (100%) 120 (100%) 222 (100%) 98 (100%) 
Is there a plan to share 
ipd 
27 (100%) 120 (100%) 222 (100%) 98 (100%) 
Description of plan to 
share ipd 
27 (100%) 120 (100%) 222 (100%) 98 (100%) 
PubMed ID 11 (40.7%) 26 (21.7%) 37 (16.7%) 6 (6.1%) 
Study references 27 (100%) 120 (100%) 222 (100%) 98 (100%) 
Citation for study 
references 






TABLE 2 Frequency and proportion of trials with a given variable completed within four 
periods 













 I II III IV 
Results reported 27 (100%) 120 (100%) 222 (100%) 98 (100%) 
Yes 4 (14.8) 23 (19.2%) 30 (13.5%) 0 (0%) 
No 23 (85.2%) 97 (80.8%) 192 
(86.5%) 
98 (100%) 
Study has at least one facility 
in USA 
27 (100%) 113 (94.2%) 190 
(85.6%) 
89 (90.8%) 
Yes 15 (55.6%) 71 (59.2%) 89 (40.1%) 38 (38.8%) 
No 12 (44.4%) 42 (35.0%) 101 
(45.5%) 
51 (52.0%) 
Study has just one facility 27 (100%) 120 (100%) 222 (100%) 98 (100%) 
Yes 13 (48.1%) 38 (31.7%) 117 
(52.7%) 
62 (63.3%) 
No 14 (51.9%) 82 (68.3%) 105 
(47.3%) 
36 (36.7%) 
Type of arm 9 (33.3%) 57 (47.5%) 162 
(73.0%) 
73 (74.5%) 
Active Comparator 1 (3.7%) 5 (4.2%) 18 (8.1%) 12 (12.2%) 
Experimental 8 (29.6%) 45 (37.5%) 121 
(54.5%) 
55 (56.1%) 
No Intervention 0 (0%) 3 (2.5%) 5 (2.3%) 1 (1.0%) 
            Placebo Comparator 0 (0%) 0 (0%) 3 (1.4%) 0 (0%) 
            Sham Comparator 0 (0%) 0 (0%) 1 (0.5%) 0 (0%) 
            Other 0 (0%) 4 (3.3%) 14 (6.3%) 5 (5.1%) 
Are results primary or 
secondary outcomes 
15 (55.6%) 98 (81.7%) 220 
(99.1%) 
98 (100%) 
Primary 15 (55.6%) 93 (77.5%) 216 
(97.3%) 
93 (94.9%) 
Secondary 0 (0%) 5 (4.2%) 3 (1.4%) 5 (5.1%) 
Other 0 (0%) 0 (0%) 1 (0.5%) 0 (0%) 
Type of allocation 8 (29.6%) 52 (43.3%) 100 
(45.0%) 
42 (42.9%) 
Non-Randomized 1 (3.7%) 20 (16.7%) 25 (11.3%) 11 (11.2%) 
Randomized 7 (25.9%) 32 (26.7 %) 75 (33.8%) 31 (31.6%) 








0 (0%) 1 (0.8%) 5 (2.3%) 4 (4.1%) 
Factorial Assignment 0 (0%) 1 (0.8%) 0 (0%) 1 (1.0%) 
Parallel Assignment 2 (7.4%) 33 (27.5%) 83 (37.4%) 34 (34.7%) 
Sequential 0 (0%) 0 (0%) 0 (0%) 1 (1.0%) 
Single Group 
Assignment 
8 (29.6%) 27 (22.5%) 76 (34.2%) 33 (33.7%) 
Observational model 2 (7.4%) 18 (15.0%) 52 (23.4%) 25 (25.5%) 
Case Control 1 (3.7%) 1 (0.8%) 3 (1.4%) 0 (0%) 
Case-Control 0 (0%) 1 (0.8%) 4 (1.8%) 7 (7.1%) 
Case-Crossover 0 (0%) 0 (0%) 1 (0.5%) 1 (1.0%) 
Case-Only 0 (0%) 4 (3.3%) 23 (10.4%) 1 (1.0%) 
Cohort 1 (3.7%) 12 (10.0%) 17 (7.7%) 11 (11.2%) 
Family-Based 0 (0%) 0 (0%) 1 (0.5%) 0 (0%) 
Other 0 (0%) 0 (0%) 3 (1.4%) 5 (5.1%) 
Primary purpose 24 (88.9%) 93 (77.5%) 164 
(73.9%) 
73 (74.5%) 
Basic Science 0 (0%) 0 (0%) 2 (0.9%) 1 (1.0%) 
Device Feasibility 0 (0%) 0 (0%) 1 (0.5%) 1 (1.0%) 
Diagnostic 0 (0%) 1 (0.8%) 4 (1.8%) 6 (6.1%) 
Health Services 
Research 
0 (0%) 0 (0%) 1 (0.5%) 0 (0%) 
Prevention 0 (0%) 12 (10.0%) 24 (10.8%) 10 (10.2%) 
Supportive Care 0 (0%) 9 (7.5%) 25 (11.3%) 15 (15.3%) 
Treatment 24 (88.9%) 71 (59.2%) 102 
(45.9%) 
33 (33.7%) 
Other 0 (0%) 0 (0%) 5 (2.3%) 7 (7.1%) 
Observational timing 2 (7.4%) 20 (16.7%) 55 (24.8%) 25 (25.5%) 
Cross-Sectional 0 (0%) 2 (1.7%) 3 (1.4%) 7 (7.1%) 
Retrospective 0 (0%) 6 (5.0%) 20 (9.0%) 3 (3.1%) 
Prospective 2 (7.4%) 11 (9.2%) 30 (13.5%) 14 (14.3%) 
Other 0 (0%) 1 (0.8%) 2 (0.9%) 1 (1.0%) 
Type of masking 13 (48.1%) 47 (39.2%) 166 
(74.8%) 
73 (74.5%) 
None (Open-Label) 12 (44.4%) 64 (53.3%) 125 
(56.3%) 
59 (60.2%) 
Single 1 (3.7%) 2 (1.7%) 15 (6.8%) 4 (4.1%) 
Double 0 (0%) 5 (4.2%) 12 (5.4%) 6 (6.1%) 
Triple 0 (0%) 0 (0%) 3 (1.4%) 1 (1.0%) 
Quadruple 0 (0%) 2 (1.7%) 11 (5.0%) 3 (3.1%) 
Was subject masked? - 6 (5.0%) 29 (13.1%) 9 (9.2%) 
Yes - 6 (5.0%) 29 (13.1) 9 (9.2%) 




Yes - 3 (2.5%) 13 (5.9%) 6 (6.1%) 
Was investigator masked? - 4 (3.3%) 23 (10.4%) 8 (8.2%) 
Yes - 4 (3.3%) 23 (10.4%) 8 (8.2%) 
Was outcome accessor 
masked? 
- 5 (4.2%) 27 (12.2%) 8 (8.2%) 
Yes - 5 (4.2%) 27 (12.2%) 8 (8.2%) 
Sampling method 2 (7.4%) 20 (16.7%) 53 (23.9%) 25 (25.5%) 
Non-Probability 
Sample 
2 (7.4%) 12 (10.0%) 46 (20.7%) 18 (18.4%) 
Probability Sample 0 (0%) 8 (6.7%) 7 (3.2%) 7 (7.1%) 
Gender 27 (100%) 120 (100%) 222 (100%) 98 (100%) 
All 27 (100%) 119 (99.2%) 214 
(96.4%) 
96 (98.0%) 
Female 0 (0%) 1 (0.8%) 6 (2.7%) 2 (2.0%) 
Male 0 (0%) 0 (0%) 2 (0.9%) 0 (0%) 
Were healthy volunteers 
eligible? 
27 (100%) 120 (100%) 221 
(99.5%) 
95 (96.9%) 
            Yes 0 (0%) 9 (7.5%) 17 (7.7%) 21 (21.4%) 
            No 27 (100%) 111 (92.5%) 204 
(91.9%) 
74 (75.5%) 
Study status 1 (3.7%) 11 (9.2%) 52 (23.4%) 58 (59.2%) 
Active, not recruiting 0 (0%) 0 (0%) 2 (0.9%) 0 (0%) 
Completed 0 (0%) 0 (0%) 0 (0%) 1 (1.0%) 
Not yet recruiting 0 (0%) 0 (0%) 2 (0.9%) 3 (3.1%) 
Recruiting 1 (3.7%) 11 (9.2%) 48 (21.6%) 54 (55.1%) 
Intervention or exposure 25 (92.6%) 112 (93.3%) 202 
(91.0%) 
91 (92.9%) 
Behavioral 0 (0%) 11 (9.2%) 35 (15.8%) 13 (13.3%) 
Biological 7 (25.9%) 26 (21.7%) 13 (5.9%) 2 (2.0%) 
Combination Product 0 (0%) 0 (0%) 0 (0%) 1 (1.0%) 
Device 0 (0%) 0 (0%) 7 (3.2%) 7 (7.1%) 
Diagnostic Test 0 (0%) 0 (0%) 1 (0.5%) 7 (7.1%) 
Dietary Supplement 0 (0%) 0 (0%) 4 (1.8%) 0 (0%) 
Drug 16 (59.3%) 57 (47.5%) 95 (42.8%) 31 (31.6%) 
Genetic 0 (0%) 3 (2.5%) 13 (5.9%) 1 (1.0%) 
Procedure 2 (7.4%) 8 (6.7%) 7 (3.2%) 6 (6.1%) 
Radiation 0 (0%) 0 (0%) 5 (2.3%) 0 (0%) 
Other 0 (0%) 7 (5.8%) 22 (9.9%) 23 (23.5%) 
Type of non-inferiority - 9 (7.5%) 11 (5.0%) 0 (0%) 
Non-inferiority - 0 (0%) 1 (0.5%) 0 (0%) 
Non-inferiority or 
Equivalence 
- 2 (1.7%) 2 (0.9%) 0 (0%) 




Superiority or Other 
(legacy) 
- 1 (0.8%) 4 (1.8%) 0 (0%) 
Other - 4 (3.3%) 3 (1.4%) 0 (0%) 
One or two-sided confidence 
interval 
- 6 (5.0%) 9 (4.1%) 0 (0%) 
            1-sided - 2 (1.7%) 0 (0%) 0 (0%) 
            2-sided - 4 (3.3%) 9 (4.1%) 0 (0%) 
Outcome type 4 (14.8%) 23 (19.2%) 30 (13.5%) 0 (0%) 
Primary 0 (0%) 6 (5.0%) 6 (2.7%) 0 (0%) 
Secondary 4 (14.8%) 17 (14.2%) 23 (10.4%) 0 (0%) 
Other-Prespecified 0 (0%) 0 (0%) 1 (0.5%) 0 (0%) 
Type of adverse event 4 (14.8%) 23 (19.2%) 222 (100%) 0 (0%) 
Serious 4 (14.8%) 18 (15.0%) 29 (13.1%) 0 (0%) 
Other 0 (0%) 5 (4.2%) 1 (0.5%) 0 (0%) 
Type of adverse event 
assessment 
4 (14.8%) 12 (10.0%) 20 (9.0%) 0 (0%) 
Non-systematic 
Assessment 
0 (0%) 3 (2.5%) 2 (0.9%) 0 (0%) 
Systematic 
Assessment 
4 (14.8%) 9 (7.5%) 18 (8.1%) 0 (0%) 
Organ system affected by 
adverse event 
4 (14.8%) 23 (19.2%) 30 (13.5%) 0 (0%) 
            General disorders 0 (0%) 3 (2.5%) 0 (0%) 0 (0%) 
            Infections and   
infestations 
0 (0%) 1 (0.8%) 0 (0%) 0 (0%) 
            Investigations 0 (0%) 1 (0.8%) 0 (0%) 0 (0%) 
Metabolism and 
Nutrition 
0 (0%) 0 (0%) 1 (0.5%) 0 (0%) 
            Musculoskeletal 0 (0%) 0 (0%) 1 (0.5%) 0 (0%) 
            Neoplasms benign, 
malignant and unspecified 
(including cysts and polyps)  
0 (0%) 1 (0.8%) 1 (0.5%) 0 (0%) 
            Nervous 2 (7.4%) 0 (0%) 1 (0.5%) 0 (0%) 
            Pregnancy, 
puerperium and perinatal 
0 (0%) 1 (0.8%) 0 (0%) 0 (0%) 
            Product Issues 0 (0%) 0 (0%) 1 (0.5%) 0 (0%) 
            Psychiatric 0 (0%) 2 (1.7%) 0 (0%) 0 (0%) 
            Renal and urinary 1 (3.7%) 0 (0%) 1 (0.5%) 0 (0%) 
            Respiratory, thoracic 
and mediastinal 
0 (0%) 5 (4.2%) 3 (1.4%) 0 (0%) 
            Skin and 
subcutaneous tissue 




            Surgical and medical 
procedures 
0 (0%) 0 (0%) 1 (0.5%) 0 (0%) 
            Total 0 (0%) 3 (2.5%) 10 (4.5%) 0 (0%) 
            Vascular 1 (3.7%) 6 (5.0%) 9 (4.1%) 0 (0%) 
Type of result reported 4 (14.8%) 23 (19.2%) 30 (13.5%) 0 (0%) 
Baseline 4 (14.8%) 21 (17.5%) 22 (9.9%) 0 (0%) 
Outcome 0 (0%) 1 (0.8%) 6 (2.7%) 0 (0%) 
Participant Flow 0 (0%) 1 (0.8%) 0 (0%) 0 (0%) 
Reported Event 0 (0%) 0 (0%) 2 (0.9%) 0 (0%) 
Type of sponsor 27 (100%) 120 (100%) 222 (100%) 98 (100%) 
Industry 0 (0%) 14 (11.7%) 46 (20.7%) 18 (18.4%) 
NIH 2 (7.4%) 4 (3.3%) 5 (2.3%) 0 (0%) 
Other 25 (92.6%) 102 (85.0%) 171 
(77.0%) 
80 (81.6%) 
Was sponsor the lead or 
collaborator?  
27 (100%) 120 (100%) 222 (100%) 98 (100%) 
Collaborator 0 (0%) 1 (0.8%) 0 (0%) 0 (0%) 
Lead 27 (100%) 119 (99.2%) 222 (100%) 98 (100%) 
Type of study 27 (100%) 120 (100%) 222 (100%) 98 (100%) 
Interventional 24 (88.9%) 96 (80.0%) 166 
(74.8%) 
73 (74.5%) 
Observational 3 (11.1%) 24 (20.0%) 55 (24.8%) 25 (25.5%) 
Observational 
(Patient Registry) 
0 (0%) 0 (0%) 1 (0.5%) 0 (0%) 
Overall status of study 27 (100%) 120 (100%) 222 (100%) 98 (100%) 
Active, not recruiting  0 (0%) 8 (6.7%) 24 (10.8%) 7 (7.1%) 





0 (0%) 0 (0%) 1 (0.5%) 3 (3.1%) 
Not yet recruiting 0 (0%) 0 (0%) 0 (0%) 16 (16.3%) 
Recruiting 1 (3.7%) 2 (1.7%) 34 (15.3%) 57 (58.2%) 
Suspended 0 (0%) 0 (0%) 0 (0%) 1 (1.0%) 
Terminated 1 (3.7%) 7 (5.8%) 21 (9.5%) 1 (1.0%) 
Withdrawn 0 (0%) 4 (3.3%) 11 (5.0%) 3 (3.1%) 
Unknown Status 7 (25.9%) 22 (18.3%) 21 (9.5%) 1 (1.0%) 
Last reported status of study 7 (25.9%) 22 (18.3%) 21 (9.5%) 1 (1.0%) 
Active, Not 
Recruiting 
7 (25.9%) 12 (10.0%) 1 (0.5%) 0 (0%) 
Not yet recruiting 0 (0%) 1 (0.8%) 2 (0.9%) 0 (0%) 
Recruiting 0 (0%) 9 (7.5%) 18 (8.1%) 1 (1.0%) 






Early Phase I 0 (0%) 1 (0.8%) 4 (1.8%) 3 (3.1%) 
Phase 1 0 (0%) 13 (10.8%) 27 (12.2%) 11 (11.2%) 
Phase 1/Phase 2 0 (0%) 2 (1.7%) 11 (5.0%) 7 (7.1%) 
Phase 2 11 (40.7%) 32 (26.7%) 37 (16.7%) 6 (6.1%) 
Phase 2/Phase 3 0 (0%) 0 (0%) 3 (1.4%) 0 (0%) 
Phase 3 10 (37.0%) 27 (22.5%) 14 (6.3%) 7 (7.1%) 
Phase 4 1 (3.7%) 5 (4.2%) 12 (5.4%) 5 (5.1%) 
N/A 2 (7.4%) 16 (13.3%) 58 (26.1%) 34 (34.7%) 
Number of arms 9 (33.3%) 57 (47.5%) 162 
(73.0%) 
73 (74.5%) 
1 6 (22.2%) 19 (15.8%) 67 (30.2%) 31 (31.6%) 
2 1 (3.7%) 28 (23.3%) 65 (29.3%) 35 (35.7%) 
3 0 (0%) 3 (2.5%) 18 (8.1%) 2 (2.0%) 
4 1 (3.7%) 3 (2.5%) 6 (2.7%) 3 (3.1%) 
5 0 (0%) 1 (0.8%) 2 (0.9%) 1 (1.0%) 
7 0 (0%) 2 (1.7%) 3 (1.4%) 0 (0%) 
8 0 (0%) 1 (0.8%) 0 (0%) 0 (0%) 
9 1 (3.7%) 0 (0%) 0 (0%) 0 (0%) 
11 0 (0%) 0 (0%) 1 (0.5%) 0 (0%) 
12 0 (0%) 0 (0%) 0 (0%) 1 (1.0%) 
Number of groups 1 (3.7%) 14 (11.7%) 30 (13.5%) 13 (13.3%) 
1 0 (0%) 6 (5.0%) 18 (8.1%) 2 (2.0%) 
2 1 (3.7%) 6 (5.0%) 8 (3.6%) 8 (8.2%) 
3 0 (0%) 2 (1.7) 3 (1.4%) 2 (2.0%) 
4 0 (0%) 0 (0%) 1 (0.5%) 1 (1.0%) 
Does study have expanded 
access 
27 (100%) 118 (98.3%) 221 
(99.5%) 
97 (99.0%) 
No 27 (100%) 118 (98.3%) 221 
(99.5%) 
97 (99.0%) 
Does study have a data and 
safety monitoring committee 
11 (40.7%) 75 (62.5%) 199 
(89.6%) 
84 (85.7%) 
Yes 5 (18.5%) 40 (33.3%) 89 (40.1%) 32 (32.7%) 
No 6 (22.2%) 35 (29.2%) 110 
(49.5%) 
52 (53.1%) 
Does study involve a FDA-
regulated drug 
- 7 (5.8%) 38 (17.1%) 97 (99.0%) 
Yes - 3 (2.5%) 16 (7.2%) 21 (21.4%) 
No - 4 (3.3%) 22 (9.9%) 76 (77.6%) 
Does study involve a FDA-
regulated device 
- 7 (5.8%) 38 (17.1%) 97 (99.0%) 
Yes - 0 (0%) 1 (0.5%) 1 (1.0%) 




Product manufactured in and 
exported from US 
- - 6 (2.7%) 90 (91.8%) 
Yes - - 3 (1.4%) 4 (4.1%) 
No - - 3 (1.4%) 4 (4.1%) 
Is there a plan to share ipd 4 (14.8%) 3 (2.5%) 67 (30.2%) 98 (100%) 
            Yes 0 (0%) 0 (0%) 20 (9.0%) 8 (8.2%) 
No 4 (14.8%) 2 (1.7%) 36 (16.2%) 40 (40.8%) 






TABLE 3 Characteristics [n (%)] of completed studies and studies terminated/withdrawn 
due to poor accrual (total N=105) 






 Completed  
 
 
n = 87 
Terminated/withd
rawn due to poor 
accrual 
n = 18 
 
Enrollment   95 (90.5) 
         1-100 64 (79.0) 13 (92.9) 77 (81.1) 
         101-1,000 13 (16.0) 1 (7.1) 14 (14.7) 
         >1,000 4 (4.9) 0 (0) 4 (4.2) 
Primary Purpose   102 (97.1) 
        Basic science 0 (0) 0 (0) 0 (0) 
        Device feasibility 1 (1.2) 0 (0) 1 (1.0) 
        Diagnostic 3 (3.6) 0 (0) 3 (2.9) 
        Health services research 0 (0) 0 (0) 0 (0) 
        Prevention 15 (17.9) 3 (16.7) 18 (17.6) 
        Screening 0 (0) 0 (0) 0 (0) 
        Supportive care 12 (14.3) 4 (22.2) 16 (15.7) 
        Treatment 51 (60.7) 11 (61.1) 62 (60.8) 
        Other 2 (2.4) 0 (0) 2 (2.0) 
Intervention type   105 (100) 
         Behavioral 18 (20.7) 3 (16.7) 21 (20.0) 
         Biological 18 (20.7) 4 (22.2) 22 (21.0) 
         Combination product 0 (0) 0 (0) 0 (0) 
         Device 3 (3.4) 0 (0) 3 (2.9) 
         Diagnostic test 0 (0) 0 (0) 0 (0) 
         Dietary supplement 0 (0) 0 (0) 0 (0) 
         Drug 38 (43.7) 10 (55.6) 48 (45.7) 
         Genetic 0 (0) 0 (0) 0 (0) 
         Procedure 3 (3.4) 1 (5.6) 4 (3.8) 
         Radiation 1 (1.1) 0 (0) 1 (1.0) 
         Other 6 (6.9) 0 (0) 6 (5.7) 
Phase   105 (100) 
        Early phase I 2 (2.3) 1 (5.6) 3 (2.9) 
        Phase I 22 (25.3) 3 (16.7) 25 (23.8) 
        Phase I/Phase II 4 (4.6) 0 (0) 4 (3.8) 
        Phase II 20 (23.0) 7 (38.9) 27 (25.7) 
        Phase II/Phase III 0 (0) 0 (0) 0 (0) 




        Phase IV 0 (0) 0 (0) 0 (0) 
        Not applicable 29 (33.3) 5 (27.8) 34 (32.4) 
Interventional Study Model   90 (85.7) 
        Crossover assignment 2 (2.7) 2 (11.8) 4 (4.4) 
        Factorial assignment 0 (0) 0 (0) 0 (0) 
        Parallel assignment 29 (39.7) 8 (47.1) 37 (41.1) 
        Sequential assignment 0 (0) 0 (0) 0 (0) 
        Single group assignment 42 (57.5) 7 (41.2) 49 (54.4) 
Allocation   53 (50.5) 
         Non-randomized 7 (16.7) 3 (27.3) 10 (18.9) 
         Randomized 35 (83.3) 8 (72.7) 43 (81.1) 
Arm type   90 (85.7) 
         Active comparator 5 (6.8) 2 (12.5) 7 (7.8) 
         Experimental 60 (81.1) 13 (81.3) 73 (81.1) 
         No intervention 2 (2.7) 0 (0) 2 (2.2) 
         Placebo comparator 2 (2.7) 0 (0) 2 (2.2) 
         Sham comparator 0 (0) 1 (6.3) 1 (1.1) 
         Other 5 (6.8) 0 (0) 5 (5.6) 
Number of arms   90 (85.7) 
        1 32 (43.2) 6 (37.5) 38 (42.2) 
        2 31 (41.9) 10 (62.5) 41 (45.6) 
        3 4 (5.4) 0 (0) 4 (4.4) 
        4 or more 7 (9.5) 0 (0) 7 (7.8) 
Masking   93 (88.6) 
         None (Open label) 60 (80.0) 14 (77.8) 74 (79.6) 
         Single 6 (8.0) 1 (5.6) 7 (7.5) 
         Double 5 (6.7) 2 (11.1) 7 (7.5) 
         Triple 1 (1.3) 0 (0) 1 (1.1) 
         Quadruple 3 (4.0) 1 (5.6) 4 (4.3) 
End point of study   22 (21.0) 
         Safety 0 (0) 1 (100.0) 1 (4.5) 
         Efficacy 1 (4.8) 0 (0) 1 (4.5) 
         Safety and efficacy 17 (81.0) 0 (0) 17 (77.3) 
         Other, includes 
bioavailability and 
bioequivalence studies 
3 (14.3) 0 (0) 3 (13.6) 
 
Number of primary outcomes   96 (91.4) 
         1 57 (73.1) 11 (61.1) 68(70.8) 
         >1 21 (26.9) 7 (38.9) 28(29.2) 
Sponsor   105 (100) 
         Children’s Oncology 
Group (COG) 
18 (20.7) 2 (11.1) 20 (19.0) 




         Individual 0 (0) 1 (5.6) 1 (1.0) 
         Institution outside the 
US (other than universities 
and hospitals) 
1 (1.1) 0 (0) 1 (1.0) 
         NIH 3 (3.4) 1 (5.6) 4 (3.8) 
         University/hospital 42 (48.3) 8 (44.4) 50 (47.6) 
Number facilities 
participating in trial 
  105 (100) 
         1 40 (46.0) 9 (50.0) 49 (46.7) 
         >1 47 (54.0) 9 (50.0) 56 (53.3) 
Primary disease   105 (100) 
         Leukemia 23 (26.4) 2 (11.1) 25 (23.8) 
         Brain and spinal cord 16 (18.4) 4 (22.2) 20 (19.0) 
         Neuroblastoma 4 (4.6) 1 (5.6) 5 (4.8) 
         Wilm’s tumor 1 (1.1) 0 (0) 1 (1.0) 
         Lymphoma 1 (1.1) 0 (0) 1 (1.0) 
         Rhabdomyosarcoma 1 (1.1) 0 (0) 1 (1.0) 
         Retinoblastoma 5 (5.7) 3 (16.7) 8 (7.6) 
         Multiple types of cancer 30 (34.5) 4 (22.2) 34 (32.4) 
         Other 6 (6.9) 4 (22.2) 10 (9.5) 
Data and safety monitoring 
committee 
  88 (83.8) 
         Yes 38 (52.8) 13 (81.3) 51 (58.0) 







TABLE 4 Chi-square test of independence for completed and terminated/withdrawn study due to poor accrual 
Variable Study status  
(N = 105) 
      
Completed  
(n = 87) 
Terminated 
or withdrawn 
due to poor 
accrual 
(n = 18) 


















Enrollment 81 14 95      
         1-100 64 (79.0) 13 (92.9)  - 1 .294* .29 .04-2.37 
         >100 17 (21.0) 1 (7.1)       
Primary Purpose 87 18 105      
        Treatment 51 (58.6) 11 (61.1)  .04 1 1.000 .90 .32-2.55 
        Other (basic science, device feasibility, 
diagnostic, health services research, prevention, 
screening, supportive care) 
36 (41.4) 7 (38.9)       
Intervention type 87 18 105      
         Drug 38 (43.7) 10 (55.6)  .85 1 .439 .62 .22-1.72 
         Other (behavioral, biological, combination 
product, device, diagnostic test, dietary 
supplement, genetic, procedure, radiation) 
49 (56.3) 8 (44.4))       
Phase 87 18 105      
        Early (early phase I, phases I, I/II, II) 48 (55.2) 11 (61.1)  - 2 .930* ** ** 
        Late (phases II/III, III, IV) 10 (11.5) 2 (11.1)       
        Not applicable 29 (33.3) 5 (27.8)       




        Parallel group 29 (39.7) 8 (47.1)  .31 1 .596 .74 .26-2.14 
        Not parallel 44 (60.3) 9 (52.9)       
Allocation**   53       
Arm type 74 16 90      
         Experimental 60 (81.1) 13 (81.3)   1 1.000* .99 .25-3.95 
         Other (active comparator, no intervention, 
placebo comparator, sham comparator, other) 
14 (18.9) 3 (18.8)       
Number of arms 74 16 90      
        1 32 (43.2) 6 (37.5)  .18 1 .784 1.27 .42-3.86 
       >1 42 (56.8) 10 (62.5)       
Masking 75 18 93       
         No (open label) 60 (80.0) 14 (77.8)   1 1.00* 1.14 .33-3.98 
         Yes 15 (20.0) 4 (22.2)       
End point of study 87 18 105      
         Safety 24 (27.6) 4 (22.2)   3 .825* ** ** 
         Safety and efficacy 24 (27.6) 7 (38.9)       
         Efficacy 10 (11.5) 2 (11.1)       
         Other (includes bioavailability and 
bioequivalence studies) 
29 (33.3) 5 (27.8)       
Number of primary outcomes 78  18  96      
          1 57 (73.1) 11 (61.1)  1.01 1 .390 1.73 .59-5.04 
          >1 21 (26.9) 7 (38.9)       
Sponsor 87  18 105      
         Industry 23 (26.4) 6 (33.3)   2 .843* ** ** 
           University/hospital 42 (48.3) 8 (44.4)       
         Other (COG, individual, institution 
outside US other than universities and hospitals, 
NIH) 




Number of participating facilities 87 18 105      
         1 40 (46.0) 9 (50.0) 49 .10 1 .800 .85 .31-2.35 
         >1 47 (54.0) 9 (50.0) 56      
Primary disease 87 18 105      
         Single most common types (leukemia, 
brain and spinal cord, neuroblastoma, Wilm’s 
tumor, lymphoma, rhabdomyosarcoma, 
retinoblastoma) 
51 (58.6) 10 (55.6)  .06 1 1.000 1.13 .41-3.15 
         Other cancers and multiple types 36 (41.4) 8 (44.4)       
Data and safety monitoring committee 72 16 88      
          Yes 38 (52.8) 13 (81.3) 51 4.36 1 .050 3.88 1.02-
14.78 
          No 34 (47.2) 3 (18.8) 37      
*Fisher’s exact test performed because expected frequency < 5 in cells 







TABLE 5 Multiple logistic regression for completed and terminated/withdrawn study due 
to poor accrual 
 
Variables in the Equation 
 B S.E. Wald df p value OR 
95% C.I. for OR 
Lower Upper 
 Data and Safety 
Monitoring Committee 
1.233 .709 3.019 1 .082 3.430 .854 13.779 









 Cancer is the second-leading cause of death among children in the United 
States.[1] Clinical trials are the conduit to new effective therapies for children with 
cancer because they ascertain whether new drug discoveries are safe and effective.[2] 
However, inadequate accrual is a significant barrier to the completion of trials as only 
two-thirds of children with cancer are treated on clinical trials.[3] More children with 
cancer should be enrolled on clinical trials to enable successful completion of oncology 
trials, thus facilitating timely availability of new effective therapies. The purposes of this 
dissertation compendium underpin several gaps in the identification of 1) barriers to 
enrollment in pediatric oncology clinical trials and 2) trial-level predictors of early 
termination of pediatric oncology trials due to poor accrual. The synthesis of the findings 
from the scoping and systematic reviews suggests associations between trial-level factors 
and early trial termination of pediatric oncology trials due to poor accrual. The analysis 
of pediatric clinical trials data reported in ClinicalTrials.gov did not demonstrate trial-
level predictors of early trial termination of pediatric oncology trials due to poor accrual, 
most likely due to not including important factors such as eligibility criteria and trial 
complexity. Further research is recommended to examine the discrepancies between 
findings of the literature reviews and exploratory analysis, with attention on the predictor 
variables with larger effect sizes in the exploratory analysis. Future trials should be 
designed considering trial-level factors such as eligibility criteria and interventional study 





Two frameworks guided the literature searches and organization of 
results/discussion in this dissertation compendium. The modified Socioecological Model 
(SEM) addresses influential factors of clinical trial accrual at the trial, 
individual/intrapersonal, interpersonal, organizational, community, and policy levels.[4] 
The first manuscript demonstrated that factors impacting accrual and completion of 
oncology clinical trials operate at multiple levels. Bennette et al.’s[5] conceptual model 
of trial-level factors associated with low trial accrual has the following four critical 
domains for assessing trial-level factors associated with low trial accrual: background, 
disease-related, treatment-related, and trial design. The second and third manuscripts 
identified trial-level factors within the four domains. 
Manuscript #1: Scoping review: Barriers and facilitators to enrollment in pediatric 
oncology clinical trials 
 
 The first manuscript in this dissertation, Barriers and Facilitators to Enrollment 
in Pediatric Oncology Clinical Trials, investigated the literature to determine the 
currently known barriers and facilitators to enrollment in oncology clinical trials for 
children. Merely 60% of pediatric cancer patients receive therapy by participating in a 
clinical trial.[3] Clinical trials are the means by which new potential therapies for cancer 
and its symptoms are tested for their safety and efficacy before being marketed.[5] These 
clinical trials often face obstacles to enrollment and completion due to their increasing 
costs during a time when sponsors and participating sites have limited resources.[6,7] 
Also, clinical trial enrollment is challenging due to the uncertainty of a new 




Enrollment is important because a clinical trial’s success is based upon having an 
adequate sample size to produce valid results.[8]  
Accepted for publication in Pediatric Nursing journal, the scoping review was 
directed by Arksey and O’Malley’s [9] methodological framework and ascertained 
barriers and facilitators to enrollment in pediatric oncology clinical trials. Findings from 
the review demonstrated trial-level barriers included lack of an available trial, trials 
closed to accrual, and eligibility criteria. Individual factors associated with enrollment 
included age, sex, race/ethnicity, insurance status, cancer characteristics, and motivation. 
Interpersonal factors included parents’ desire for continuity of care by healthcare 
providers, physicians’ discussions with parents and children about clinical trials, and 
physicians’ attitudes about clinical trials. Organizational factors that influenced 
enrollment included local availability of a clinical trial and continuity of care. No studies 
of community or policy-level barriers and facilitators were found. The review’s findings 
included a gap in theoretically based knowledge about trial-level barriers and facilitators 
to enrollment in pediatric oncology clinical trials. 
Manuscript #2: Trial-level Factors Affecting Accrual and Completion of Oncology 
Clinical Trials: A Systematic Review 
 
The second manuscript in this dissertation, Trial-level Factors Affecting Accrual 
and Completion of Oncology Clinical Trials: A Systematic Review, explores the literature 
to identify trial-level factors that affect accrual and/or completion of oncology clinical 
trials, gaps in the literature, and prospects for research in the future. Oncology clinical 
trials are known to terminate early or be extended due to inadequate accrual, negatively 




or early terminated trials hinder the marketing of new safe and effective cancer therapies 
for patients.  
Guided by the PRISMA statement, a sample of the literature was systematically 
selected for the review.[12] Studies were included if they were: a) empirical studies that 
analyzed trial-level factors that influenced accrual and/or completion of oncology trials 
and b) studies that analyzed data from state, regional, national, or international clinical 
trial databases. The systematic review’s findings indicated the following background 
factors were associated with oncology clinical trial accrual and/or completion: sponsor, 
number and location of participating institutions, competing trials, time of trial opening, 
and fast-track status. Disease-related factors included the annual incidence and type(s) of 
targeted cancer. Several types of treatment such as drugs, radiation and surgery were 
examined in the studies. Trial design factors included trial development time, eligibility 
criteria, randomization, sample size, trial phase, placebo use, and required protocol 
procedures and their timing. Future studies with a theoretical foundation could be 
conducted to assess the association between trial-level factors and accrual/trial 
completion. Researchers also could concurrently investigate background, disease-related, 
treatment-related, and trial design factors that affect accrual for specific cancers and 
populations. 
Manuscript #3: Predictors of Early Termination of Pediatric Oncology Clinical 
Trials Due to Poor Accrual: An Exploratory Analysis 
 
The third manuscript in this dissertation, Predictors of Early Termination of 
Pediatric Oncology Clinical Trials Due to Poor Accrual: An Exploratory Analysis, 




variables in the ClinicalTrials.gov database over the past 20 years for pediatric oncology 
clinical trials and  investigates trial-related factors that may affect early termination of 
pediatric oncology clinical trials due to low accrual. Due to low patient participation, 
pediatric oncology clinical trials are often terminated early or extended. The Institute of 
Medicine (IOM) has urged for improvement in the selection, conduct and completion of 
oncology trials.[13]   
The amount of available data in ClinicalTrials.gov differed among variables 
across different time periods that were based on the effective dates of regulations 
affecting ClinicalTrials.gov. Of the following trial-level factors, none were significantly 
associated (p < 0.05) with early termination of pediatric oncology trials: enrollment, 
primary purpose, intervention type, phase, interventional study model, allocation, arm 
type, number of arms, masking, primary end points, number of primary outcomes, 
sponsor, number of participating facilities, primary disease, and data monitoring 
committee. However, the use of a data and safety monitoring committee and number of 
primary outcomes warrant further investigation due to their odds ratios. None of the trial-
level factors combined were predictive of early termination of pediatric oncology trials 
due to low accrual. Future research can build upon this study by including pediatric 
oncology clinical trials conducted throughout the world, rather than just those within the 
United States. In addition, researchers can examine additional variables in the 






The results of the individual manuscripts and the triangulation of their findings 
contribute to the science of clinical trials. The scoping review found a gap in theoretically 
based knowledge about trial-level barriers and facilitators to enrollment in pediatric 
oncology clinical trials. The gap in knowledge supported the conduct of manuscript #3, 
Predictors of Early Termination of Pediatric Oncology Clinical Trials Due to Poor 
Accrual: An Exploratory Analysis. Also, due to gap in knowledge about trial-level 
barriers and facilitators to enrollment in pediatric oncology clinical trials, currently 
known trial-level barriers and facilitators to enrollment in adult oncology clinical trials 
were investigated in the second manuscript, Trial-level Factors Affecting Accrual and 
Completion of Oncology Clinical Trials: A Systematic Review. Several trial-level barriers 
and facilitators to enrollment in adult oncology clinical trials were identified, such as 
enrollment, intervention type, phase, allocation, arm type, sponsor, number of 
participating facilities, primary disease. These trial-level barriers and facilitators were 
subsequently utilized as independent variables in the analysis reported in manuscript #3 
to determine predictors of early termination of pediatric oncology clinical trials due to 
poor accrual. Other possible predictor variables were identified in ClinicalTrials.gov, 
which included primary purpose, number of primary outcomes, interventional study 
model, number of arms, and the use of a data and safety monitoring committee. As 
indicated in Manuscript #3, none of the examined independent variables were predictive 
of early termination of pediatric oncology trials due to low accrual. The basic information 




factors, without having to code textual data on criteria factors and/or individually search 
for the trials in the literature to glean additional details. 
The triangulation of the three manuscripts’ findings contribute to the science of 
clinical trials by identifying possible predictors of early termination of pediatric oncology 
clinical trials due to poor accrual. National organizations, such as the Institute of 
Medicine (IOM), have called for improvements in clinical trials. The IOM has appealed 
for increased efficiency in clinical trials, higher rates of completion, and prioritization of 
the most feasible and needed trials.[14] Evidence from the literature reviews performed 
in this dissertation suggest that for pediatric oncology clinical trials to successfully 
complete in an efficient manner, knowledge of trial-level factors that affect accrual and 
completion of those trials is warranted.[5,15] In particular, knowledge of non-modifiable 
trial-level factors such as trial phase may also enable healthcare providers to educate 
patients, possibly increasing acceptance of and participation in trials.[6,15] Evidence 
from this dissertation also indicates knowledge of trial-level factors that affect accrual 
and completion of trials may also allow sponsors and institutions to accurately predict a 
trial’s accrual and completion which, in turn, enables prioritization of the most feasible 
trials.[7]  
This dissertation also contributes to the science of clinical trials by demonstrating 
additional research is needed to identify predictors of enrollment in pediatric oncology 
clinical trials. This is evidenced by trial-level barriers and facilitators identified in 
manuscripts #1 and #2 failing to align with the results of the exploratory analysis in 




oncology clinical trials due to poor accrual. Based on these findings, predictors of 
enrollment in pediatric oncology clinical trials may differ from those in adult oncology 
trials. 
Limitations 
This dissertation has limitations. The scoping and systematic reviews may not 
have included all available literature due to inadvertently omitted search terms. Since 
there was only one reviewer, studies included in the reviews could not be assessed for 
inter-rater reliability based on inclusion and exclusion criteria. A limitation of the third 
manuscript, an exploratory analysis of trial-related factors that may affect early 
termination of pediatric oncology clinical trials due to low accrual, was lack of inclusion 
of all clinical trials conducted worldwide. Some trials are not required to be registered on 
ClinicalTrials.gov.[16] No other clinical trial registries were utilized due to the technical 
difficulties in the identification and elimination of duplicate trials. Bias may also be 
present since only one database, which could contain inaccurate data, was utilized.[17]  
Other limitations of this dissertation are related to changes in regulations over the 
last two decades which resulted in discrepancies in the type and completeness of data that 
investigators submitted into the database during that time frame.[18] The amount of 
available data differs among variables and across different time periods affected by new 
regulations. Other than variables pertaining to results, recent trials have more 
completeness of variables than those trials conducted in the more distant past, possibly 
skewing this study’s results. Results could also differ based on the cut-off dates for time 




study design was not required to be entered on ClinicalTrials.gov until implementation in 
2008 of the Food and Drug Administration Amendments Act of 2007 (FDAAA). It is 
likely study design was entered for fewer trials in 2008 than 2010 due to the lag in 
sponsors’ knowledge of and compliance to the Act. Therefore, there would be different 
percentages of completeness for the study design variable data for period 2 and period 3 
if the cutoff for those periods was 2010 rather than 2008. If 2010 had been utilized as the 
cutoff date, the percentage of completeness for study design would likely have been 
higher for period 2 and period 3. Results could also differ based on the date of the dataset 
as sponsors/principal investigators can retrospectively update information on 
ClinicalTrials.gov.[20] Finally, some of the groups within variables were small. This 
increases the likelihood of type II errors, possibly resulting in missed identified 
predictors. 
Lessons Learned 
  There were many lessons learned in the dissertation process. First, large databases 
such as ClinicalTrials.gov can be challenging to utilize as multiple strategies and much 
time may be required to successfully import data files into SPSS. Second, it is important 
to ensure the computer to be used for file import into SPSS and analyses has sufficient 
memory and processing capabilities. Third, after files are imported, additional variables 
need to be created and data correctly coded to facilitate analyses; this can be time-
consuming. Labeling of variables is of the utmost importance for organization when 
many variables are present. Fourth, differences exist between missing data and data not 




Fifth, many clinical trials cases are necessary when there are several variables and groups 
for chi-square analyses. The researcher was unable to perform all chi-square analyses that 
were originally planned due to this issue. Thus, groups were combined if appropriate and 
Fisher’s exact test was performed. 
Future Research 
Future advancements in this area of scholarship specific to the program of trial-
level research include an expansion of this dissertation’s investigation of trial-related 
factors that may predict early termination of pediatric oncology clinical trials due to low 
accrual. Future analyses of ClinicalTrials.gov data will include clinical trials throughout 
the world, rather than merely those in the United States. Additional independent variables 
that were not included in the compendium’s third manuscript due to time constraints will 
be investigated. For example, the specific types of eligibility criteria which will require 
manual review and coding as that variable is in free text format within the 
ClinicalTrials.gov dataset. This knowledge may further assist with the strategic design of 
pediatric oncology clinical trials to avoid inadequate accrual and early termination of the 
trials. The results from a future manuscript describing these analyses will drive 
subsequent studies evaluating strategies to offset the effects of trial-level factors that 
adversely impact accrual and trial completion.  
Conclusion 
The major findings from this body of scholarship suggest there may be trial-level 
factors that predict accrual and/or completion of pediatric oncology clinical trials. 




trials that have been conducted worldwide and incorporate multiple trial databases such 
as ClinicalTrials.gov and European Union Drug Regulating Authorities Clinical Trials 
Database (EudraCT). The design of future oncology clinical trials should address 
approaches to minimize trial-level factors such as burdensome eligibility criteria and a 
single participating facility that are associated with or predictive of early trial termination 
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Appendix B Glossary of Common Site Terms for ClinicalTrials.gov 
Term Definition 
Accepts healthy volunteers A type of eligibility criteria that indicates whether people 
who do not have the condition/disease being studied can 
participate in that clinical study. 
Active comparator arm An arm type in which a group of participants receives 
an intervention/treatment considered to be effective (or 
active) by health care providers. 
Adverse event An unfavorable change in the health of a participant, 
including abnormal laboratory findings, that happens 
during a clinical study or within a certain amount of time 
after the study has ended. This change may or may not 
be caused by the intervention/treatment being studied. 
Age or age group A type of eligibility criteria that indicates the age a 
person must be to participate in a clinical study. This 
may be indicated by a specific age or the following age 
groups: 
The age groups are: 
• Child (birth-17) 
• Adult (18-64) 
• Older Adult (65+) 
 
All-cause mortality A measure of all deaths, due to any cause, that occur 
during a clinical study. 
Allocation A method used to assign participants to an arm of a 
clinical study. The types of allocation are randomized 
allocation and nonrandomized. 
Arm A group or subgroup of participants in a clinical trial that 
receives a specific intervention/treatment, or no 
intervention, according to the trial's protocol. 
Arm type A general description of the clinical trial arm. It 
identifies the role of the intervention that participants 




comparator arm, placebo comparator arm, sham 
comparator arm, and no intervention arm. 
Baseline characteristics Data collected at the beginning of a clinical study for all 
participants and for each arm or comparison group. 
These data include demographics, such as age, 
sex/gender, race and ethnicity, and study-specific 
measures (for example, systolic blood pressure, prior 
antidepressant treatment). 
Canceled submission Indicates that the study sponsor or investigator recalled a 
submission of study results before quality control (QC) 
review took place. If the submission was canceled on or 
after May 8, 2018, the date is shown. After submission of 
study results, a study record cannot be modified until QC 
review is completed, unless the submission is canceled. 
Certain agreements Information required by the Food and Drug 
Administration Amendments Act of 2007. In general, 
this is a description of any agreement between the 
sponsor of a clinical study and the principal 
investigator (PI) that does not allow the PI to discuss the 
results of the study or publish the study results in a 
scientific or academic journal after the study is 
completed. 
Certification A sponsor or investigator may submit a certification to 
delay submission of results information if they are 
applying for FDA approval of a new drug or device, or 
new use of an already approved drug or device. A 
sponsor or investigator who submits a certification can 
delay results submission up to 2 years after 
the certification/extension first submitted date, unless 
certain events occur sooner. 
Clinical study A research study involving human volunteers (also called 
participants) that is intended to add to medical 
knowledge. There are two types of clinical 
studies: interventional studies (also called clinical trials) 
and observational studies. 





identifier (NCT number) 
The unique identification code given to each clinical 
study upon registration at ClinicalTrials.gov. The format 
is "NCT" followed by an 8-digit number (for example, 
NCT00000419). 
Collaborator An organization other than the sponsor that provides 
support for a clinical study. This support may include 
activities related to funding, design, implementation, data 
analysis, or reporting. 
Condition/disease The disease, disorder, syndrome, illness, or injury that is 
being studied. On ClinicalTrials.gov, conditions may 
also include other health-related issues, such as lifespan, 
quality of life, and health risks. 
Contact The name and contact information for the person who 
can answer enrollment questions for a clinical study. 
Each location where the study is being conducted may 
also have a specific contact, who may be better able to 
answer those questions. 
Country The Country field is used to find clinical studies with 
locations in a specific country.  
Cross-over assignment A type of intervention model describing a clinical trial in 
which groups of participants receive two or more 
interventions in a specific order. For example, two-by-
two cross-over assignment involves two groups of 
participants. One group receives drug A during the initial 
phase of the trial, followed by drug B during a later 
phase. The other group receives drug B during the initial 
phase, followed by drug A. So during the trial, 
participants "cross over" to the other drug. All 
participants receive drug A and drug B at some point 
during the trial but in a different order, depending on the 
group to which they are assigned. 
Data Monitoring 
Committee (DMC) 
A group of independent scientists who monitor the safety 
and scientific integrity of a clinical trial. The DMC can 
recommend to the sponsor that the trial be stopped if it is 
not effective, is harming participants, or is unlikely to 
serve its scientific purpose. Members are chosen based 




the particular trial. Also called a data safety and 
monitoring board, or DSMB. 
Early Phase 1 (formerly 
listed as Phase 0) 
A phase of research used to describe exploratory trials 
conducted before traditional phase 1 trials to investigate 
how or whether a drug affects the body. They involve 
very limited human exposure to the drug and have no 
therapeutic or diagnostic goals (for example, screening 
studies, microdose studies). 
Eligibility criteria The key requirements that people who want to 
participate in a clinical study must meet or the 
characteristics they must have. Eligibility criteria consist 
of both inclusion criteria (which are required for a person 
to participate in the study) and exclusion criteria (which 
prevent a person from participating). Types of eligibility 
criteria include whether a study accepts healthy 
volunteers, has age or age group requirements, or is 
limited by sex. 
Enrollment The number of participants in a clinical study. The 
"estimated" enrollment is the target number of 
participants that the researchers need for the study. 
Exclusion criteria A type of eligibility criteria. These are reasons that a 
person is not allowed to participate in a clinical study. 
Expanded access A way for patients with serious diseases or conditions 
who cannot participate in a clinical trial to gain access to 
a medical product that has not been approved by the U.S. 
Food and Drug Administration (FDA). Also called 
compassionate use. There are different expanded access 
types. 
Expanded access status • Available: Expanded access is currently available 
for this investigational treatment, and patients 
who are not participants in the clinical study may 
be able to gain access to the drug, biologic, or 
medical device being studied. 
• No longer available: Expanded access was 
available for this intervention previously but is 
not currently available and will not be available 




• Temporarily not available: Expanded access is 
not currently available for this intervention but is 
expected to be available in the future. 
• Approved for marketing: The intervention has 
been approved by the U.S. Food and Drug 
Administration for use by the public. 
 
Expanded access type Describes the category of expanded access under U.S. 
Food and Drug Administration (FDA) regulations. There 
are three types of expanded access: 
• Individual Patients: Allows a single patient, with 
a serious disease or condition who cannot 
participate in a clinical trial, access to a drug or 
biological product that has not been approved by 
the FDA. This category also includes access in an 
emergency situation. 
• Intermediate-size Population: Allows more than 
one patient (but generally fewer patients than 
through a Treatment IND/Protocol) access to a 
drug or biological product that has not been 
approved by the FDA. This type of expanded 
access is used when multiple patients with the 
same disease or condition seek access to a 
specific drug or biological product that has not 
been approved by the FDA. 
• Treatment IND/Protocol: Allows a large, 
widespread population access to a drug or 
biological product that has not been approved by 
the FDA. This type of expanded access can only 
be provided if the product is already being 
developed for marketing for the same use as the 
expanded access use. 
 
Experimental arm An arm type in which a group of participants receives 
the intervention/treatment that is the focus of the clinical 
trial. 
 
Extension request In certain circumstances, a sponsor or investigator may 
request an extension to delay the standard results 




the primary completion date). The request for an 
extension must demonstrate good cause (for example, the 
need to preserve the scientific integrity of an 
ongoing masked trial). All requests must be reviewed 
and granted by the National Institutes of Health. This 
process for review and granting of extension requests is 
being developed. 
 
Factorial assignment A type of intervention model describing a clinical trial in 
which groups of participants receive one of several 
combinations of interventions. For example, two-by-two 
factorial assignment involves four groups of participants. 
Each group receives one of the following pairs of 
interventions: (1) drug A and drug B, (2) drug A and a 
placebo, (3) a placebo and drug B, or (4) a placebo and a 
placebo. So during the trial, all possible combinations of 
the two drugs (A and B) and the placebos are given to 
different groups of participants. 
 
First posted The date on which the study record was first available on 
ClinicalTrials.gov. There is typically a delay of a few 
days between the date the study sponsor or investigator 
submitted the study record and the first posted date. 
 
First submitted The date on which the study sponsor or investigator first 
submitted a study record to ClinicalTrials.gov. There is 
typically a delay of a few days between the first 
submitted date and the record's availability on 
ClinicalTrials.gov (the first posted date). 
 
First submitted that met 
QC criteria 
The date on which the study sponsor or investigator first 
submits a study record that is consistent with National 
Library of Medicine (NLM) quality control (QC) 
review criteria. The sponsor or investigator may need to 
revise and submit a study record one or more times 
before NLM's QC review criteria are met. It is the 
responsibility of the sponsor or investigator to ensure 
that the study record is consistent with the NLM QC 
review criteria. 
 
Food and Drug 
Administration 
U.S. Public Law 110-85, which was enacted on 
September 27, 2007. Section 801 of FDAAA amends 




Amendments Act of 2007, 
Section 801 (FDAAA 801) 
expand ClinicalTrials.gov and create a clinical 
study results database.  
 
Funder type Describes the organization that provides funding or 
support for a clinical study. This support may include 
activities related to funding, design, implementation, data 
analysis, or reporting. Organizations listed 
as sponsors and collaborators for a study are considered 
the funders of the study. ClinicalTrials.gov refers to four 
types of funders: 
• U.S. National Institutes of Health 
• Other U.S. Federal agencies (for example, Food 
and Drug Administration, Centers for Disease 
Control and Prevention, or U.S. Department of 
Veterans Affairs) 
• Industry (for example: pharmaceutical and device 
companies) 
• All others (including individuals, universities, 
and community-based organizations) 
 
Gender-based eligibility A type of eligibility criteria that indicates whether 
eligibility to participate in a clinical study is based a 
person's self-representation of gender identity or gender 
(yes, no). Gender is distinct from sex. 
 
Group/cohort A group or subgroup of participants in an observational 
study that is assessed for biomedical or health outcomes. 
 
Human subjects protection 
review board 
A group of people who review, approve, and monitor the 
clinical study's protocol. Their role is to protect the rights 
and welfare of people participating in a study (referred to 
as human research subjects), such as reviewing 
the informed consent form. The group typically includes 
people with varying backgrounds, including a 
community member, to make sure that research activities 
conducted by an organization are completely and 
adequately reviewed. Also called an institutional review 
board, or IRB, or an ethics committee. 
 
Inclusion criteria A type of eligibility criteria. These are the reasons that a 





Informed consent A process used by researchers to communicate to 
potential and enrolled participants the risks and potential 
benefits of participating in a clinical study. 
 
Informed consent form 
(ICF) 
The document used in the informed consent or process. 
Intervention model The general design of the strategy for assigning 
interventions to participants in a clinical study. Types of 
intervention models include: single group 
assignment, parallel assignment, cross-over assignment, 
and factorial assignment. 
 
Intervention/treatment A process or action that is the focus of a clinical study. 
Interventions include drugs, medical devices, procedures, 
vaccines, and other products that are either 
investigational or already available. Interventions can 
also include noninvasive approaches, such as education 




A type of clinical study in which participants are 
assigned to groups that receive one or 
more intervention/treatment (or no intervention) so that 
researchers can evaluate the effects of the interventions 
on biomedical or health-related outcomes. The 
assignments are determined by the study's protocol. 
Participants may receive diagnostic, therapeutic, or other 
types of interventions. 
 
Investigator A researcher involved in a clinical study. Related terms 
include site principal investigator, site sub-investigator, 
study chair, study director, and study principal 
investigator. 
 
Last update posted The most recent date on which changes to a study 
record were made available on ClinicalTrials.gov. There 
may be a delay between when the changes were 
submitted to ClinicalTrials.gov by the study's sponsor or 
investigator (the last update submitted date) and the last 
update posted date. 
 
Last update submitted The most recent date on which the study sponsor or 
investigator submitted changes to a study record to 




days between the last update submitted date and when 
the date changes are posted on ClinicalTrials.gov 
(the last update posted date). 
 
Last update submitted that 
met QC criteria 
The most recent date on which the study sponsor or 
investigator submitted changes to a study record that are 
consistent with National Library of Medicine 
(NLM) quality control (QC) review criteria. It is the 
responsibility of the sponsor or investigator to ensure 
that the study record is consistent with the NLM QC 
review criteria. 
 
Last verified The most recent date on which the study sponsor or 
investigator confirmed the information about a clinical 
study on ClinicalTrials.gov as accurate and current. If a 
study with a recruitment status of recruiting; not yet 
recruiting; or active, not recruiting has not been 
confirmed within the past 2 years, the study's recruitment 
status is shown as unknown. 
 
Listed location countries Countries in which research facilities for a study are 
located. A country is listed only once, even if there is 
more than one facility in the country. The list includes all 
countries as of the last update submitted date; any 
country for which all facilities were removed from 
the study record are listed under removed location 
countries. 
 
Location terms In the search feature, the Location terms field is used to 
narrow a search by location-related terms other than 
Country, State, and City or distance. For example, you 
may enter a specific facility name (such as National 
Institutes of Health Clinical Center) or a part of a facility 
name (such as Veteran for studies listing Veterans 
Hospital or Veteran Affairs in the facility name). Note: 
Not all study records include this level of detail about 
locations. 
 
Masking A clinical trial design strategy in which one or more 
parties involved in the trial, such as the investigator or 
participants, do not know which participants have been 
assigned which interventions. Types of masking include: 






NCT number A unique identification code given to each clinical study 
record registered on ClinicalTrials.gov. The format is 
"NCT" followed by an 8-digit number (for example, 
NCT00000419). Also called the ClinicalTrials.gov 
identifier. 
 
No intervention arm An arm type in which a group of participants does not 
receive any intervention/treatment during the clinical 
trial. 
 
Observational study A type of clinical study in which participants are 
identified as belonging to study groups and are assessed 
for biomedical or health outcomes. Participants may 
receive diagnostic, therapeutic, or other types of 
interventions, but the investigator does not assign 
participants to a specific interventions/treatment. 
A patient registry is a type of observational study. 
 
Observational study model The general design of the strategy for identifying and 
following up with participants during an observational 
study. Types of observational study models include 
cohort, case-control, case-only, case-cross-over, ecologic 
or community studies, family-based, and other. 
 
Other adverse event An adverse event that is not a serious adverse event, 
meaning that it does not result in death, is not life-
threatening, does not require inpatient hospitalization or 
extend a current hospital stay, does not result in an 
ongoing or significant incapacity or interfere 
substantially with normal life functions, and does not 
cause a congenital anomaly or birth defect; it also does 
not put the participant in danger and does not require 
medical or surgical intervention to prevent one of the 
results listed above. 
 
Other study IDs Identifiers or ID numbers other than the NCT 
number that are assigned to a clinical study by the study's 
sponsor, funders, or others. These numbers may include 
unique identifiers from other trial registries and National 





Other terms In the search feature, the Other terms field is used to 
narrow a search. For example, you may enter the name 
of a drug or the NCT number of a clinical study to limit 
the search to study records that contain these words. 
 
Outcome measure For clinical trials, a planned measurement described in 
the protocol that is used to determine the effect of 
an intervention/treatment on participants. 
For observational studies, a measurement or observation 
that is used to describe patterns of diseases or traits, or 
associations with exposures, risk factors, or treatment. 
Types of outcome measures include primary outcome 
measure and secondary outcome measure. 
 
Parallel assignment A type of intervention model describing a clinical trial in 
which two or more groups of participants receive 
different interventions. For example, a two-arm parallel 
assignment involves two groups of participants. One 
group receives drug A, and the other group receives drug 
B. So during the trial, participants in one group receive 
drug A "in parallel" to participants in the other group, 
who receive drug B. 
 
Participant flow A summary of the progress of participants through each 
stage of a clinical study, by study arm or group/cohort. 
This includes the number of participants who started, 
completed, and dropped out of the study. 
 
Patient registry A type of observational study that collects information 
about patients' medical conditions and/or treatments to 
better understand how a condition or treatment affects 
patients in the real world. 
 
Phase The stage of a clinical trial studying a drug or biological 
product, based on definitions developed by the U.S. Food 
and Drug Administration (FDA). The phase is based on 
the study's objective, the number of participants, and 
other characteristics. There are five phases: Early Phase 
1 (formerly listed as Phase 0), Phase 1, Phase 2, Phase 3, 
and Phase 4. Not Applicable is used to describe trials 
without FDA-defined phases, including trials of devices 





Phase 1 A phase of research to describe clinical trials that focus 
on the safety of a drug. They are usually conducted with 
healthy volunteers, and the goal is to determine the 
drug's most frequent and serious adverse events and, 
often, how the drug is broken down and excreted by the 
body. These trials usually involve a small number of 
participants. 
-typically 20-80 participants1 
Phase 2 A phase of research to describe clinical trials that gather 
preliminary data on whether a drug works in people who 
have a certain condition/disease (that is, the drug's 
effectiveness). For example, participants receiving the 
drug may be compared to similar participants receiving a 
different treatment, usually an inactive substance (called 
a placebo) or a different drug. Safety continues to be 
evaluated, and short-term adverse events are studied. 
-typically 100 – 300 participants1 
Phase 3 A phase of research to describe clinical trials that gather 
more information about a drug's safety and effectiveness 
by studying different populations and different dosages 
and by using the drug in combination with other drugs. 
These studies typically involve more participants. 
-typically 1,000 – 3,000 participants1 
Phase 4 A phase of research to describe clinical trials occurring 
after FDA has approved a drug for marketing. They 
include postmarket requirement and commitment studies 
that are required of or agreed to by the study sponsor. 
These trials gather additional information about a drug's 
safety, efficacy, or optimal use. 
Phase Not Applicable Describes trials without FDA-defined phases, including 
trials of devices or behavioral interventions. 
 
Placebo An inactive substance or treatment that looks the same 
as, and is given in the same way as, an active drug 
or intervention/treatment being studied. 
 
Placebo comparator arm An arm type in which a group of participants receives 
a placebo during a clinical trial. 
 
Primary completion date The date on which the last participant in a clinical study 
was examined or received an intervention to collect final 
data for the primary outcome measure. Whether the 
clinical study ended according to the protocol or was 




with more than one primary outcome measure with 
different completion dates, this term refers to the date on 
which data collection is completed for all the primary 
outcome measures. The "estimated" primary completion 
date is the date that the researchers think will be the 
primary completion date for the study. 
 
Primary outcome measure In a clinical study's protocol, the planned outcome 
measure that is the most important for evaluating the 
effect of an intervention/treatment. Most clinical studies 
have one primary outcome measure, but some have more 
than one. 
 
Primary purpose The main reason for the clinical trial. The types of 
primary purpose are: treatment, prevention, diagnostic, 
supportive care, screening, health services research, basic 
science, and other. 
 
Principal investigator (PI) The person who is responsible for the scientific and 
technical direction of the entire clinical study. 
 
Protocol The written description of a clinical study. It includes the 
study's objectives, design, and methods. It may also 
include relevant scientific background and statistical 
information. 
 
Quality control (QC) 
review 
National Library of Medicine (NLM) staff perform a 
limited review of submitted study records for apparent 
errors, deficiencies, or inconsistencies. NLM staff 
identify potential major and advisory issues and provide 
comments directly to the study sponsor or investigator. 
Major issues identified in QC review must be addressed 
or corrected (see First submitted that met QC 
criteria and Results first submitted that met QC criteria). 
Advisory issues are suggestions to help improve the 
clarity of the record. NLM staff do not verify the 
scientific validity or relevance of the submitted 
information. The study sponsor or investigator is 
responsible for ensuring that the studies follow all 
applicable laws and regulations. 
 
Randomized allocation A type of allocation strategy in which participants are 





Recruitment status • Not yet recruiting: The study has not started 
recruiting participants. 
• Recruiting: The study is currently recruiting 
participants. 
• Enrolling by invitation: The study is selecting its 
participants from a population, or group of 
people, decided on by the researchers in advance. 
These studies are not open to everyone who 
meets the eligibility criteria but only to people in 
that particular population, who are specifically 
invited to participate. 
• Active, not recruiting: The study is ongoing, and 
participants are receiving an intervention or being 
examined, but potential participants are not 
currently being recruited or enrolled. 
• Suspended: The study has stopped early but may 
start again. 
• Terminated: The study has stopped early and will 
not start again. Participants are no longer being 
examined or treated. 
• Completed: The study has ended normally, and 
participants are no longer being examined or 
treated (that is, the last participant's last visit has 
occurred). 
• Withdrawn: The study stopped early, before 
enrolling its first participant. 
• Unknown: A study on ClinicalTrials.gov whose 
last known status was recruiting; not yet 
recruiting; or active, not recruiting but that has 
passed its completion date, and the status has not 
been last verified within the past 2 years. 
 
Registration The process of submitting and updating summary 
information about a clinical study and its protocol, from 
its beginning to end, to a structured, public Web-





Countries that appeared under listed location 
countries but were removed from the study record by the 





Reporting group A grouping of participants in a clinical study that is used 
for summarizing the data collected during the study. This 
grouping may be the same as or different from a study 
arm or group. 
 
Responsible party The person responsible for submitting information about 
a clinical study to ClinicalTrials.gov and updating that 
information. Usually the study sponsor or investigator. 
 
Results database A structured online system, such as the 
ClinicalTrials.gov results database, that provides the 
public with access to registration and summary results 
information for completed or terminated clinical studies. 
A study with results available on ClinicalTrials.gov is 
described as having the results "posted." 
Note: The ClinicalTrials.gov results database became 
available in September 2008. Older studies are unlikely 
to have results available in the database. 
 
Results delayed Indicates that the sponsor or investigator submitted 
a certification or extension request. 
 
Results first posted The date on which summary results information was first 
available on ClinicalTrials.gov. There is typically a delay 
between the date the study sponsor or investigator first 
submits summary results information (the results first 
submitted date) and the results first posted date. 
 
Results first submitted The date on which the study sponsor or investigator first 
submits a study record with summary results 
information. There is typically a delay between the 
results first submitted date and when summary results 
information becomes available on ClinicalTrials.gov 
(the results first posted date). 
 
Results first submitted that 
met QC criteria 
The date on which the study sponsor or investigator first 
submits a study record with summary results information 




(NLM) quality control (QC) review criteria. The sponsor 
or investigator may need to revise and submit results 
information one or more times before NLM's QC review 
criteria are met. It is the responsibility of the sponsor or 
investigator to ensure that the study record is consistent 
with the NLM QC review criteria. 
 
Results returned after 
quality control review 
The date on which the National Library of Medicine 
provided quality control (QC) review comments to the 
study sponsor or investigator. The sponsor or 
investigator must address major issues identified in the 
review comments. If there is a date listed for results 
returned after quality control review, but there is not a 
subsequent date listed for results submitted to 
ClinicalTrials.gov, this means that the submission is 
pending changes by the sponsor or investigator. 
 
Results submitted to 
ClinicalTrials.gov 
Indicates that the study sponsor or investigator has 
submitted summary results information for a clinical 
study to ClinicalTrials.gov but the quality control (QC) 
review process has not concluded. 
The results submitted date indicates when the study 
sponsor or investigator first submitted summary results 
information or submitted changes to summary results 
information. Submissions with changes are typically in 
response to QC review comments from the National 
Library of Medicine (NLM). If there is a date listed for 
results submitted to ClinicalTrials.gov, but there is not a 
subsequent date listed for results returned after quality 
control review, this means that the submission is pending 




In a clinical study's protocol, a planned outcome measure 
that is not as important as the primary outcome measure 
for evaluating the effect of an intervention but is still of 
interest. Most clinical studies have more than one 
secondary outcome measure. 
 
Serious adverse event An adverse event that results in death, is life-threatening, 
requires inpatient hospitalization or extends a current 
hospital stay, results in an ongoing or significant 
incapacity or interferes substantially with normal life 




Medical events that do not result in death, are not life-
threatening, or do not require hospitalization may be 
considered serious adverse events if they put the 
participant in danger or require medical or surgical 
intervention to prevent one of the results listed above. 
 
Sex A type of eligibility criteria that indicates the sex of 
people who may participate in a clinical study (all, 
female, male). Sex is a person's classification as female 
or male based on biological distinctions. Sex is distinct 
from gender-based eligibility. 
 
Sham comparator arm An arm type in which a group of participants receives a 
procedure or device that appears to be the same as the 
actual procedure or device being studied but does not 
contain active processes or components. 
 
Single group assignment A type of intervention model describing a clinical trial in 
which all participants receive the same 
intervention/treatment. 
 
Sponsor The organization or person who initiates the study and 
who has authority and control over the study. 
 
State  The State field is used to find clinical studies with 
locations in a specific state within the United States. If 
you choose United States in the Country field, you can 
search for studies with locations in a specific state. 
 
Statistical analysis plan 
(SAP) 
The written description of the statistical considerations 
and methods for analyzing the data collected in 
the clinical study. 
 
Status Indicates the current recruitment status or the expanded 
access status. 
 
Study completion date The date on which the last participant in a clinical study 
was examined or received an intervention/treatment to 
collect final data for the primary outcome 
measures, secondary outcome measures, and adverse 
events (that is, the last participant's last visit). The 
"estimated" study completion date is the date that the 





Study design The investigative methods and strategies used in the 
clinical study. 
 
Study documents Refers to the type of documents that the study sponsor or 
principal investigator may add to their study record. 
These include a study protocol, statistical analysis plan, 
and informed consent form. 
 
Study IDs Identifiers that are assigned to a clinical study by the 
study's sponsor, funders, or others. They include unique 
identifiers from other trial study registries and National 
Institutes of Health grant numbers. Note: 
ClinicalTrials.gov assigns a unique identification code to 
each clinical study registered on ClinicalTrials.gov. Also 
called the NCT number, the format is "NCT" followed 
by an 8-digit number (for example, NCT00000419). 
 
Study record An entry on ClinicalTrials.gov that contains a summary 
of a clinical study's protocol information, including 
the recruitment status; eligibility criteria; contact 
information; and, in some cases, summary results. Each 
study record is assigned a ClinicalTrials.gov identifier, 
or NCT number. 
 
Study registry A structured online system, such as ClinicalTrials.gov, 
that provides the public with access to summary 
information about ongoing and completed clinical 
studies. 
 
Study results A study record that includes the summary results posted 
in the ClinicalTrials.gov results database. Summary 
results information includes participant flow, baseline 
characteristics, outcome measures, and adverse 
events (including serious adverse events). 
 
Study start date The actual date on which the first participant was 
enrolled in a clinical study. The "estimated" study start 
date is the date that the researchers think will be the 
study start date. 
 
Study type Describes the nature of a clinical study. Study types 
include interventional studies (also called clinical 
trials), observational studies (including patient 





Submitted date The date on which the study sponsor or investigator 
submitted a study record that is consistent with National 
Library of Medicine (NLM) quality control (QC) review 
criteria. 
 
Title The official title of a protocol used to identify a clinical 
study or a short title written in language intended for the 
lay public. 
 
Title acronym The acronym or initials used to identify a clinical study 
(not all studies have one). For example, the title acronym 
for the Women's Health Initiative is "WHI." 
 
U.S. Agency for 
Healthcare Research and 
Quality (AHRQ) 
An agency within the U.S. Department of Health and 
Human Services. AHRQ's mission is to produce 
evidence to make health care safer, higher quality, more 
accessible, equitable, and affordable, and to work within 
the U.S. Department of Health and Human Services and 
with other partners to make sure that the evidence is 
understood and used. 
 
U.S. Food and Drug 
Administration (FDA) 
An agency within the U.S. Department of Health and 
Human Services. The FDA is responsible for protecting 
the public health by making sure that human and 
veterinary drugs, vaccines and other biological products, 
medical devices, the Nation's food supply, cosmetics, 
dietary supplements, and products that give off radiation 
are safe, effective, and secure. 
 
Unknown A type of recruitment status. It identifies a study on 
ClinicalTrials.gov whose last known status was 
recruiting; not yet recruiting; or active, not recruiting but 
that has passed its completion date, and the status has not 
been verified within the past 2 years. Studies with an 
unknown status are considered closed studies. 
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